


The Journal of the American Diabetes Association

diabetes

Volume 24 • 1975

INDEX

By Subject and Author



Copyright 1976, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, DAVID M. KIPNIS, M.D., *St. Louis*

ASSOCIATE EDITORS: PAUL E. LACY, M.D., *St. Louis* • FRANZ M. MATSCHINSKY, M.D., *St. Louis*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, ANTHONY S. PAGLIARA, M.D., *St. Louis* • MANAGING EDITOR, LOUIS DOYLE, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1976

LESTER BAKER, M.D., *Philadelphia*
REX S. CLEMENTS, JR., M.D., *Birmingham, Alabama*
R. PHILIP EATON, M.D., *Albuquerque*
PHILIP FELIG, M.D., *New Haven*
DONALD B. MARTIN, M.D., *Boston*
GERALD M. REAVEN, M.D., *Palo Alto*

TERM EXPIRING DECEMBER 1977

JEROME M. FELDMAN, M.D., *Durham*
RONALD K. KALKHOFF, M.D., *Milwaukee*
JOHN H. KARAM, M.D., *San Francisco*
ARTHUR A. LIKE, M.D., *Worcester*
THOMAS J. MERIMEE, M.D., *Gainesville, Fla.*
ARTHUR H. RUBENSTEIN, M.D., *Chicago*
GEORGE STEINER, M.D., *Toronto*

TERM EXPIRING DECEMBER 1978

WILLIAM L. CHICK, M.D., *Wellesley*
ALLAN L. DRASH, M.D., *Pittsburgh*
CHARLES J. GOODNER, M.D., *Seattle*
LEONARD S. JEFFERSON, JR., PH.D., *Hershey, Pa.*
BOYD E. METZGER, M.D., *Chicago*
SUMER PEK, M.D., *Ann Arbor*
DANIEL PORTE, JR., M.D., *Seattle*
ROSALYN S. YALOW, PH.D., *New York*

ABSTRACTORS

TERM EXPIRING DECEMBER 1976

IAN M. BURR, M.D., *Nashville*
THAD C. HAGEN, M.D., *Milwaukee*
HUEY G. MCDANIEL, M.D., *Birmingham, Alabama*
RICHARD REYNERTSON, M.D., *Birmingham, Alabama*
JULIO SANTIAGO, M.D., *St. Louis*
CHARLES R. SHUMAN, M.D., *Philadelphia*

TERM EXPIRING DECEMBER 1977

JEAN-PHILIPPE ASSAL, M.D., *Geneva, Switzerland*
JOHN E. GERICH, M.D., *San Francisco*
DINESH KUMAR, M.D., *Los Angeles*
VICTOR R. LAVIS, M.D., *Seattle*
THOMAS G. SKILLMAN, M.D., *Columbus, Ohio*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and

not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications:* The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing, and if possible, submitted in triplicate together with three copies of figures and photomicrographs. Authors' and coauthors' degrees should be cited.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C.

H.: The internal secretion of the pancreas. *J. Lab. Clin. Med.* 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: *Studies Concerning Glycosuria and Diabetes*. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 1 West 48th Street, New York, New York 10020.

Subscription and Advertising Information

DIABETES: The Journal of the American Diabetes Association is published every month by the Association at 1 West 48th Street, New York, New York 10020. © American Diabetes Association, Inc., 1976. All rights reserved under International and Pan-American Copyright Convention.

Professional Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$35.00 for one year; \$62.00 for two years; \$98.00 for three years. Individual copies \$3.00. Foreign postage at \$3.00 per year applies to all foreign countries, including Canada, Mexico and other

countries in the Postal Union of the Americas and Spain.

Subscriptions for medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral are \$17.50 per year plus \$3.00 for foreign postage where applicable. Subscriptions in this category may be entered or renewed for only one-year terms.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES. Checks, money orders and drafts for

subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

Information concerning the microfilm edition of this Journal may be obtained from the offices of University Microfilms, P.O. Box 1346, Ann Arbor, Michigan 48106.

All inquiries about advertising and other business matters should be addressed to the Managing Editor of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.



SUBJECT INDEX 1975

This index covers all reading matter in Volume 24 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index begins on page 38.

A

- ACETOHEXAMIDE**
and latent diabetes therapy, *443
- ACETYLCHOLINE**
and glycogen synthase and glycogenesis, *425
and insulin biosynthesis, *403
intrapancratic infusion of
and glucagon and insulin secretion, *56
- ACETYLCHOLINESTERASE**
and sciatic nerve ligation in diabetic rats, 1081-1084
- ACID-BASE BALANCE**
and renal cortical and hepatic phosphoenolpyruvate carboxylase, *525-526
- ACID MUCOPOLYSACCHARIDES**
in somatomedin assay, *385
- ACIDEMIA**
and alcoholic ketosis, 786-790
and hyperosmolar nonketotic coma, 595
- ACIDOSIS**
respiratory
and cerebrospinal fluid bicarbonate regulation, *781
- ACIDOSIS, LACTIC**
and alcoholic ketosis, 788
and diabetes
and phenformin, *428
and epinephrine poisoning, *691
and phenformin, *430, *440, 741-744
and diabetes, 791-799
and insulin therapy, 28-33
- ACIDS**
nicotinic
and fat cell metabolism, *690
and glucagon secretion, *604
- trihydroxycholanolic
and alloxan diabetes, *57
- ACOMYS CAHIRINUS**. *See* Mice, spiny
- ACROMEGALY**
and growth hormone and insulin secretion
and somatostatin, *1033-1034
and growth hormone release-inhibiting hormone, *56-57
and somatostatin effect on blood glucose, plasma growth hormone, insulin, and free fatty acids, *526
- ACTION**
in pancreatic islet cells, *605
- ADDISON'S DISEASE**
and diabetes, *695
and HL-A antigens, *387
- ADENOCARCINOMA**
of pancreas
and immunosuppressive therapy, *243
- ADENOSINE**
and lipolysis in human adipocytes, *428
- ADENOSINE DEAMINASE**
and cyclic adenosine monophosphate accumulation, lipolysis, and glucose metabolism of fat cells, *690
- ADENOSINE 5'-DIPHOSPHATE DISODIUM SALT**
in platelet aggregation study, 684-685
- ADENOSINE PHOSPHATE**
-induced platelet aggregation
and diabetes, *428
- ADENOSINE TRIPHOSPHATE**
in isolated fat cells
and cell size and insulin response, *418
- ADENYL CYCLASE**
in isolated islets of neonatal rats, 750
- ADIPOCYTES**
calcium binding to
and insulin, *395
insulin receptors of
ultrastructural studies, *395
insulin sensitivity in, *418
insulin sensitivity, 1086-1092
isolated rat
and dexamethasone effects on insulin binding and glucose transport and oxidation, *393, *1129
lipolysis by
and adenosine, *428
metabolism
and hyperlipoproteinemia without diabetes or obesity, 207-212
- ADIPOSE TISSUE**
cellularity
and metabolism in young and middle-aged women, *1127
in diabetic rats, *416
and enzymes of glucose metabolism and citrate cleavage pathway, 865-871
fatty acid synthesis by, *780
insulin receptors
and insulin and cortisol, *394
of normal and diabetic subjects
and enzymes of glucose metabolism and citrate cleavage pathway, 865-871
in obese hyperglycemic mice and streptozotocin, *688
- ADRENAL GLANDS**
catecholamine release
and tolbutamide, *1034
insufficiency

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- and diabetes and Addison's disease, *695
- receptors
- interactions with adrenocorticotrophic hormone, *781
- and tolbutamide, *414
- ADRENALECTOMY**
- and diabetes-induced resistance of ventromedial hypothalamus to gold thioglucose damage, *385
- ADRENERGIC AGENTS**
- and postgastrectomy hypoglycemia, *412, 1005-1009
- ADRENERGIC ANTAGONISTS**
- and pancreatic islet monoamine oxidase, *432
- ADRENERGIC BLOCKADE**
- and glucagon responses to starvation and hyperglycemia, *526
- and insulin secretion in diabetes, *420
- and metabolism, *1125-1126
- and plasma glucagon levels
- and rapid exsanguination, 313-315
- and somatostatin inhibition of insulin secretion, *408
- and sulfonylurea-stimulated insulin secretion, *444
- ADRENOCORTICOTROPIC HORMONE**
- ectopic
- and islet cell carcinoma, 600-603
- interactions with its adrenal receptors, *781
- and pancreatic and serum insulin and blood glucose, *688
- response
- and alloxan diabetes, *242
- AFFERENT RECEPTORS**
- and plasma insulin levels, *414
- AFRICANS**
- and diet
- and diabetes development, 762-764
- AGE**
- and adipose tissue cellularity
- and metabolism, *1127
- and cell-mediated immunity in diabetes, 37, 38
- and diabetes
- with Bell's palsy, 450, 451
- and enzymatic digestion of tendon collagen sample, 902-904
- and glucose tolerance tests in children and adolescents, 820-827
- and glucose tolerance tests in Pima Indians, 539, 545-546
- and immunoreactive glucagon responses to intravenous tolbutamide
- and chronic pancreatitis, 853
- and insulin dosage, *425
- and intraperitoneal islet transplantation of fetal and neonatal pancreas, *419
- and islet cell tumor surgery, *693
- and muscle capillary thickening and retinopathy, 286, 287
- and myelin content of rabbit sciatic nerve, 680-683
- at onset of diabetes
- and diabetic glomerulosclerosis, 2, 6
- and sciatic nerve myelin content in diabetic rabbits, *397
- and serum growth hormone levels in maturity-onset diabetics, 978
- of UGDP patients, 69, 70, 71, 79-83, 120-121
- ALANINE**
- and glucagon infusion in fasted man, *54
- glucagon stimulation of gluconeogenesis from, 574-583
- infusion
- and glucagon secretion in infants of diabetic mothers, *411
- oral, in small-for-gestational-age infants
- and blood glucose, plasma glucagon, and insulin, *1036
- stimulated growth hormone release in juvenile diabetics, *401
- ALANINE-U-¹⁴C**
- incorporation into glucose in human fetal liver explants
- and hormones, 650-656
- L-ALANINE**
- intravenous tolerance tests
- and gluconeogenesis, *604
- ALBUMIN**
- and glibenclamide binding to pancreatic beta cells, *308
- ALCOHOL. See also Ethanol**
- and pancreatitis
- and immunoreactive glucagon responses to intravenous tolbutamide, 851-855
- ALCOHOLISM**
- and blood acetaldehyde after ethanol administration, *691
- and ketosis, 785-790
- ALDOSTERONISM**
- and ketoacidosis, 190-193
- ALKALINE PHOSPHATASE**
- and chronic diabetes, 258-260
- ALKALEMIA**
- and alcoholic ketosis, 786-790
- ALKALOSIS**
- respiratory
- and cerebrospinal fluid bicarbonate regulation, *781
- ALLERGY**
- to insulin
- and lymphocyte function, 42
- ALLOGRAFTS. See also Transplantation**
- pancreaticoduodenal functional recovery of, *446
- ALLOXAN**
- and cyclic 3'5'-AMP
- and insulin release by isolated pancreatic islets, *405
- and D-glucose anomers
- and insulin biosynthesis and secretion, *404
- and insulin secretion
- and methylxanthines and cytochalasin B., *400
- toxicity, 516-522
- ALLOXAN DIABETES**
- and adrenocortical system, *242
- and brain carbohydrate and energy metabolism in mice, *781
- and cataracts in beagle dogs, 1048-1049

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

and cholesterol metabolism, *57
in dogs
and exercise, methylprednisolone,
and glucose turnover,
915-920
and gastric alpha cell function, *411
and hypothalamo-hypophysial-
adrenocortical system, *308
and insulin and glucose as modulators
of amino-acid induced
glucagon release, *692
and 3-0-methyl-D-glucopyranose as
protective agent against,
*1035
and parathyroid function, *58
and plasma glucagon, *412
protection of beta cell from, 516-522
in rabbits
and sciatic nerve myelin content
study, 680-683
in rats
and intraperitoneal islet transplanta-
tion of fetal and neonatal pan-
creas, *419
reversal of, *420
reversal by islet transplantation of organ
cultured neonatal pancreas,
*435
therapy
with intrajejunal administration of
water-in-oil-in-water insulin
emulsions, 971-975

ALUMINUM NICOTINATE
and serum cholesterol, *385

AMERICAN DIABETES ASSOCIA-
TION
annual meetings
Thirty-fourth, 390-391
Thirty-fifth, 59, 244, 311, 393-448,
527, 607, 696-701, 1038
Committees and Editorial boards,
1975-76, 1130-1134
Committees, editorial boards and state
coordinators for the organiza-
tional year, 1974-75, 59-62
Diabetes Forecast, 527
Investigator Program, 701-702
Lilly Award applications, 702
Necrology, 64, 248, 312, 392, 528,
608, 704, 784, 862, 1136
New Members, 247-248, 702-703,
861-862, 958, 1039
news of Affiliate Associations, 63, 248,
391-392, 608, 784, 862, 958,
1134-1136

news Notes, 63-64, 248, 311-312, 392,
527-528, 608, 703-704, 784,
862-863, 1039, 1136
Officers and Board of Directors,
1975-1976, 696
Personals, 312, 392, 528, 608, 784
postgraduate courses, 59, 244-247,
958, 1037-1038, 1134,
Research and Development Awards,
391, 701
Research Grants Program, 59, 1038
Research Symposia, 391, 607, 702,
782-783
Reviewers of manuscripts and books,
240-241

AMINO ACIDS
and glucose
in rat pancreatic islets, 476-487,
489-495
incorporation into protein
and insulin and glycogen, *447
-induced glucagon and insulin release
and glucose, *526
induced glucagon release
and insulin and glucose, *692
metabolism
and diabetic ketoacidosis therapy,
463-467
release
and isoproterenol, *416
stimulated glucagon secretion
in infants of diabetic mothers, *411

AMINOPHYLLINE. *See* Theophylline

AMYLASE
in rat pancreas
and gastrointestinal hormones,
*1033

ANGIOGRAPHY
and pulmonary emboli
and urokinase and streptokinase
trial, *307

ANGIOPATHY, DIABETIC
and growth hormone levels, 981

ANOMERS
glucose
and insulin release, *404
D-glucose
and insulin biosynthesis and secre-
tion, *404

ANTIBIOTICS
Strepto
and carcinoid syndrome, 670

ANTIBODIES
against angiotensin I
and plasma renin activity determi-
nations, 191-193
to cultured human insulinoma
in insulin-dependent diabetes, *401
IgG insulin
and monocomponent pork insulin,
626-627
IgG proinsulin-specific
to monocomponent pork insulin,
625-632
¹²⁵I-labeled anti-immunoglobulin G
and serum polypeptide hormone
assay, *779
to pancreatic islet cells
in insulin-dependent diabetes with
autoimmune disease, *606
to thyroglobulin and thyroid micro-
somal fraction
and autoimmune thyroiditis,
829-832

ANTIDEPRESSANT DRUGS
and insulin release, *1032

ANTIGENS
HL-A
and diabetes, 345-349, *387
-induced lymphocyte transformation
and diabetes, 36-43
and islets of Langerhans transplanta-
tion, 766-775
in twins, *402

ARGININE
glucagon response to
and diabetes therapy, 811-818
in perfused islets and perfused pan-
creas, 964-965
in prediabetic, diabetic, and normal
Pima Indians and Caucasians,
*427
-induced growth hormone release
and somatostatin, 844
infusion tests
in diabetics, 811-818
and insulin release
in perfused islets and perfused pan-
creas, 963-964
and secretin, *438
and pancreatic insulin and glucagon
release

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

in genetically diabetic Chinese hamster, 272-278
 -stimulated growth hormone release in juvenile diabetics, *401
 -stimulated insulin and glucagon secretion in normal man, 735-739
 stimulation
 and portal and peripheral blood proinsulin, insulin, and C-peptide, *1034
 stimulation tests
 and hypoglycemia and insulinoma, 535

ARTERIOSCLEROSIS
 hypertensive
 and diabetic retinopathy, *435

L-ASPARAGINASE
 and islet cell carcinoma, 600

ATROPINE
 and glycogen synthase and glycogenesis, *425

AUTOANALYZER, 449-450, 576-577

AUTOANALYZER FERRICYANIDE METHOD, 10

AUTOIMMUNE DISEASE
 and diabetes pathogenesis, *606

AUTOIMMUNE THYROIDITIS
 and carbohydrate tolerance, 829-832

AUTOIMMUNITY
 to pancreatic beta cells, *401

AZATHIOPRINE
 and diabetic pregnancy, 498

B

BARBITURATES
 and systemic hypoglycemic response, 329-335

BASEMENT MEMBRANE
 capillary
 of prospective kidney donors, *434
 glomerular
 chemical composition of, *427
 and streptozotocin diabetes, *429
 muscle capillary

in normal and diabetic children, *400
 thickening
 and diabetes, 949

BEHAVIOR DISORDERS
 and metabolic diseases, *1128

BELL'S PALSY
 and diabetes, 449-451

BETHANECHOL
 and glycogen synthase and glycogenesis, *425

BILE SALTS
 cholesterol conversion into
 and alloxan diabetes, *57

BINESIS
 in beta cells of isolated rat islets, *398

BLOOD
 acetaldehyde
 and ethanol administration in alcoholics and nonalcoholics, *691
 ammonia levels
 and therapeutic elevation of insulin-glucagon ratio, *389
 exsanguination
 and plasma glucagon levels, 313-315
 "fast" hemoglobin
 and diabetic pregnancy, *415
 fibrinolytic activity
 and diabetic retinopathy, 529-533
 flow
 and diabetes, 951
 ketone bodies
 and fructose, glyceraldehyde, and sorbitol in rats, 926-931
 lactate, creatinine and pH
 and phenformin-induced lactic acidosis in diabetics, 791-799

pH
 and diabetic coma, 595
 platelet aggregation
 and diabetes, *398, *428, 684-686, *1035
 portal and peripheral proinsulin, insulin, and C-peptide concentrations in, *1034
 red cell 2, 3-diphosphoglycerate levels
 and diabetes and vascular disease, 724-728
 and pregnancy, *415
 red cells
 and streptozotocin, *399

samples
 and alcoholic ketosis, 785
 and insulin response and carbohydrate intake study, 1073
 in starvation ketosis study, 10-16
 volume
 in uncontrolled diabetes, 190-193

BLOOD GLUCOSE. See also Blood sugar
 control
 and diabetic glomerulosclerosis, 6
 in diabetes and obesity, 187-188
 and diabetes therapy, 815-816
 and growth hormone, ACTH, cortisol, dexamethasone, and tolbutamide, *688
 during intravenous glucose tolerance tests, 20
 lowering agents
 and plasma renin activity, *429
 and oral alanine feeding in small-for-gestational-age infants, *1036
 and phenformin, 29
 and serum glucagon and insulin levels
 and acute myocardial infarction and acute coronary insufficiency, *694
 and somatostatin, 1124
 and acromegaly, *526
 in UGDP phenformin study, 88-92, 124, 125
 mean values and standard errors, 170, 171
 and water-in-oil-in-water insulin emulsions,
 in alloxan-diabetic rats, 971-975

BLOOD PRESSURE
 and cataracts and diazoxide, 1041-1049
 and diabetic retinopathy, 529
 in UGDP phenformin study patients, 92-96, 127
 mean values and standard errors, 172

BLOOD SUGAR. See also Blood glucose
 and "chemical hypoglycemia," 54
 and tris, *692

BODY. See also Weight
 fat
 and fat-cell diameter, 1091
 growth
 in obese hyperglycemic mice, *386-387
 lower extremities

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

and ischemia, and femorotibial bypass, *1129

BONE

mass
and diabetes, *398
multiple aseptic necrosis
and latent diabetes, *389

BOOK REVIEWS

Carbohydrate Metabolism in Pregnancy and the Newborn, edited by Hamish W. Sutherland and John M. Stowers, 1032
Endocrinology and Diabetes. The Thirtieth Hahnemann Symposium, edited by Leonard J. Fryston and Ralph A. Shaw, 861
Nutrients in Processed Foods, Vol. II: Proteins, edited by Philip L. White and Dean C. Fletcher, 306

BRAIN

biochemical alterations
and diabetic comas, *1126-1127
carbohydrate and energy metabolism
and alloxan diabetes, anti-insulin serum diabetes, and non-diabetic dehydration in mice, *781
electrolyte transport in
and hypoglycemic seizures and coma, *241
and insulin, *307
glucose and glycogen
and dexamethasone, *417
glucose transport and metabolism, *1129
injury
and glucose metabolism, *691
intraventricular insulin administration and insulin secretion in dog, 910-914

BROAYAS

and glucose tolerance studies, 983-986

BURNS

and hyperglucagonemia, *694
and hyperglycemia
and hyperglucagonemia, 523
and insulin resistance, *446

C

CALCIUM

antagonists
and islet function, 547-551
binding to adipocyte plasma membranes
and insulin, *395
duodenal
and parathyroid response in alloxan diabetic rats, *58
and glucose-stimulated insulin release, *1127
and glucose transport, *448
influx in beta cells
and verapamil, *400
and insulin release, 1123
and sodium-potassium adenosine-triphosphatase, *438
uptake by isolated rat islets
cobalt inhibition of, *1127
and verapamil inhibition of glucose-induced insulin release, 549-550

CALORIES

and insulin binding to receptors in obese subjects, *688
intake
and adipocyte insulin sensitivity, 1090
and protein malnutrition
and glucose tolerance and insulin secretion, *444
restriction
and insulin binding by hepatic plasma membranes from diabetic rats, *394
in UGDP study diet, 66

CAPILLARIES

basement membrane
and diabetic *Macaca nigra*, 201-206
of prospective kidney donors, *434
of diabetic dogs, 343
muscle
basement membrane changes in normal and diabetic children, *400
of South African diabetics, 286-290

CARBOHYDRATE

brain metabolism
and alloxan diabetes, anti-insulin serum diabetes, and non-diabetic dehydration in mice, *781

dietary

and basal and postprotein insulin and glucagon levels, 552-557
fatty acid biosynthesis from
and adipose tissue, *780
-induced hypertriglyceridemia, *416
intake
and biphasic insulin response to intravenous glucose, 1072-1079
intolerance
and hypertriglyceridemia, and obese children, *439
metabolism
and acute myocardial infarction, *55
and pancreatic islet cell function in thalassemia major, *430
oral
insulin responses to, 362-367, 368
insulin response to
in prediabetics and controls, *1036
protective effects against alloxan, 518-519
-stimulated insulin secretion
and phosphoinositide metabolism, *399
tolerance
and autoimmune thyroiditis, 829-832
and hypothyroidism, 922-925

CARBON DIOXIDE

in metabolism studies with C-glucose, 186-188

CARBOXYTOLBUTAMIDE

and catecholamine secretion, *414

CARCINOMA

and glucose intolerance, 664-670
and insulin injection site, *431
islet cell
and ectopic ACTH syndrome, 600-603

CARDIOTHORACIC RATIO

in UGDP phenformin study patients, 100, 128
mean values and standard errors for, 173

CARDIOVASCULAR DISEASE

and diabetic mortality, 1
and plasma renin activity
and blood glucose lowering agents, *429
prevention of
and anti-diabetic treatment, *414

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- risk factors, in UGDP patients, 69, 70, 71, 79-83
- CASE REPORTS**
- adenocarcinoma of pancreas and immuno-suppressed leukemia, *243
 - alcoholic ketosis, 785-790
 - carcinoid syndrome and glucose intolerance, 664-670
 - chronic pancreatitis in African diabetics, *694
 - diabetes and Addison's disease, *695
 - diabetic complications with anterior hypopituitarism, 1027-1030
 - diabetic pregnancy after renal transplantation, 497-501
 - epinephrine poisoning and lactic acidosis, *691
 - factual panniculitis and necrotizing fascitis in juvenile diabetic, 856-858
 - high serum immunoreactive insulin levels
 - and monoclonal immunoglobulinemia, 214-223
 - hypoglycemia
 - and insular hyperplasia, *243
 - and propranolol and insulinoma, 535-537
 - hypoglycemia and hyperinsulinemia and neurofibrosarcoma, *1128
 - hypoglycemia and pulmonary edema, *426
 - hypothermia of hypoglycemia, 859-860
 - insulin therapy in phenformin-associated lactic acidosis, 28-33
 - islet cell carcinoma and ectopic ACTH syndrome
 - and hypoglycemia, 600-603
 - islet cell tumors of pancreas, *693
 - Mauriac syndrome with villous atrophy, *242, *308
 - multiple aseptic bone necrosis and latent diabetes, *389
 - phenformin-induced lactic acidosis, *440
 - plasma C-peptide in diagnosis of factitious hyperinsulinism, *1033
 - plasma cell dyscrasia, polyneuropathy, and endocrine disturbances, *56
- CATABOLISM**
- and burns, *694
 - and semistarvation, *690
- CATARACTS**
- and diazoxide
 - in beagle dogs, 1041-1049
- CATECHOLAMINES**
- and glucagon secretion, *310
 - induced lipolysis
 - and glucocorticoids, *1127-1128
 - release
 - inhibition by tolbutamide, *1034
 - secretion
 - and tolbutamide, *414
 - and trauma, *691-692
- CAUCASIANS**
- and glucagon response to arginine, *427
 - and insulin release to intravenous glucose
 - compared with Pima Indians, *402
- CEREBROSPINAL FLUID**
- bicarbonate regulation
 - and respiratory acidosis and alkalosis, *781
- CESAREAN SECTION**
- insulin requirement after, *605
- CHILDREN. See also Diabetes Mellitus, Juvenile**
- with chemical diabetes
 - and serum proinsulin levels, 753-756
 - and tolbutamide therapy, *434
 - of conjugal diabetic parents, 452-462
 - of diabetic parents
 - and response to intravenous glucose, glucagon and tolbutamide, *433
 - and gluconeogenesis testing
 - and intravenous L-alanine tolerance tests, *604
 - glucose and lysine gastrointestinal absorption, *309
 - and glucose tolerance tests
 - age-adjusted analysis of insulin responses during, 820-827
 - intestinal absorption of glucose and lysine in, *243
 - juvenile-onset and maturity-onset diabetes in
 - and heredity, 44-52
 - and obesity
 - and carbohydrate intolerance and hypertriglyceridemia, *439
- CHINESE HAMSTERS**
- with diabetic genotype and variable phenotype
 - and insulin and glucagon release study, *409
 - genetically diabetic
 - and pancreatic responses to arginine, 272-278
 - and plasma insulin and glucagon assay, *448
- CHLORAMINE-T**
- and glucagon immunoreactivity, *1130
- CHLORMADINONE ACETATE**
- and induced diabetes in dogs, 337-343
- CHLORPROMAZINE**
- induced growth hormone release in rats
 - and hypothalamic surgery and somatostatin, *691
- CHLORPROPAMIDE**
- and hypoglycemia, *396
 - therapy
 - in diet-failed maturity-onset diabetics, *689
- CHOLESTEROL**
- metabolism
 - in diabetic rat, *57
 - and plasma lipid levels in juvenile diabetics, 672-678
- CHOLINE ACETYLASE**
- and sciatic nerve ligation in diabetic rats, 1081-1084
- CHOLINERGIC BLOCKADE**
- and probantheline
 - and hypoglycemia, *425
- CHROMATOGRAPHY**
- anion exchange
 - and preparation of "monocomponent" pork insulin, 625-626
 - gas-liquid
 - and glipizide pharmacokinetics, *437
 - in gluconeogenesis and glucagon study, 576-577
 - isolation of insulin messenger RNA by, *405
 - Sephadex G-75
 - of degradation products of insulin
 - degradation by rat liver cells, 571-572

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

- thin layer
of phospholipids of chronic diabetic
rats, 259-260
- CHROMIUM**
and glucose utilization
and infection, 350-352
- CIRRHOSIS**
and blood ammonia levels during
therapeutic elevation of
insulin-glucagon ratio, *389
- CITRATE CLEAVAGE PATHWAY**
enzymes of
in adipose tissue of normal and
diabetic subjects, 865-871
- CLOFIBRATE**
and glucagon secretion, *604, *1130
and ketonemia suppression
and insulin-deficient diabetes, *442
- COBALT**
and insulin secretion and calcium up-
take by isolated rat islets,
*1127
- COBALT CHLORIDE**
and glucagon sensitivity
and hypertriglyceridemia, *604
- COLCHICINE**
and insulin secretion, *443
- COLLAGEN**
biosynthesis
in glomerular basement membrane
of streptozotocin diabetic
rats, *429
enzymatic digestion of
and diabetes, 902-904
measurement in renal glomeruli
in diabetic and nondiabetic kidneys,
1057-1064
- COLLAGENASE**
islets isolated with
and alpha- and beta-cell secretory
responses, 961-970
- COMA, DIABETIC**
hyperosmolar, 594-599
and hyperglycemia and hyper-
glucagonemia, 523
and hypoglycemia, *241, *307
and pulmonary edema, *426
- neurologic manifestations of,
*1126-1127
nonketotic hyperosmolar
and plasma glucagon, *56
- CONCAVALIN A**
and glucose transport, *448
- CORTICOSTEROIDS**
and glucagon secretion, *310
- CORTICOTROPIN**
-stimulated lipolysis
and insulin and proinsulin, 238-239
- CORTISOL**
and adipose tissue insulin receptors,
*394
and glucagon secretion, *310
and pancreatic and serum insulin and
blood glucose, *688
secretion
and exercise in obese and diabetic
children, 758-761
and propranolol-glucagon testing,
*58
- CORTISONE**
-glucose tolerance test
and latent diabetes therapy, *443
and islet cell neogenesis, *447
- COXSACKIE B4 VIRUS**
and beta-cell necrosis, 348
and diabetes, *389
and juvenile diabetes, *386
- CREATININE**
clearance
and insulin response to oral glucose
load, 1066-1070
- CYCLIC 3'5' ADENOSINE
MONOPHOSPHATE**
accumulation
and adenosine deaminase, *690
and alloxan
and insulin release, *405
and calcium, *1127
and insulin action, *1034
output in rat pancreas
and gastrointestinal hormones,
*1033
response to glucose
in isolated islets of neonatal rats,
746-751
and somatostatin, 849
and theophylline effect on glucose
kinetics, 249
- CYCLIC GMP**
and somatostatin, 849
- CYCLIC NUCLEOTIDE PHOS-
PHODIESTERASE**
and insulin and diabetes, *444
- CYCLIC NUCLEOTIDES**
and insulin secretion and biosynthesis,
197, 198
- CYPROHEPTADINE**
and insulin secretion by isolated
perfused rat islets, 836-841
- CYSTIC FIBROSIS**
and islet-binding immunoglobulins,
233-234
- CYTOCHALASIN B**
and alloxan inhibition of insulin secre-
tion, *400
and glyceraldehyde isomers
and insulin release, *403
-induced insulin secretion, 893-894,
896-900
and L-isoleucine stimulation of
glycolysis, 482-483

D

- 1-DEAMINO-8-D-ARGININE VAS-
OPRESSIN**
and antidiuretic response in pituitary
diabetes insipidus
and glyburide, *526
- DEUTERIUM OXIDE**
and insulin release, *694
- DEXAMETHASONE**
acute and chronic
and insulin binding to isolated rat
hepatocytes and adipocytes,
*1129
and brain glucose and glycogen, *417
and insulin binding, glucose transport,
and glucose oxidation of isolated rat
adipocytes, *393
and pancreatic and serum insulin, and
blood glucose, *688
and plasma free fatty acids and blood
 β -HOB levels in fasting sub-
jects, 11-12

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

DEXTROTHYROXINE
and serum cholesterol, *385

DIABETES INSIPIDUS
and 1-deamino-8-D-arginine
vasopressin-induced an-
tididiuretic response
and glyburide, *526

DIABETES MELLITUS
and abnormal growth hormone pat-
terns
and insulin treatment, *525
and accelerated aging of human col-
lagen, 902-904
and Addison's disease, *695
and afferent receptors and taste per-
ception studies, *414
and alpha-cell dysfunction, *410
and autoimmune disease
and antibodies to pancreatic islet
cells, *606
and basement membrane thickness in
muscle capillaries
in *Macaca nigra*, 201-206
and Bell's palsy, 449-451
and bone mass, *398
and capillary thickening
and retinopathy, 286-290
and cardiomyopathy, *242, *691
and cell-mediated immunity, 36-43
chemical
and alcoholic ketosis, 788
and serum proinsulin, 753-756
and tolbutamide therapy in chil-
dren, *434
in Chinese hamsters
and plasma insulin and glucagon
levels, *448
and chromium metabolism, *406
chronic
and cell membrane composition and
turnover, 257-261
and chronic pancreatitis, *694
and chronic renal failure
and hemodialysis, *1128
control
and exogenous insulin, *401
and Coxsackie B viruses, *386, *389
and cyclic nucleotide phosphodies-
terase, *444
development
and childhood obesity, *439
diagnosis
criteria for, 641-644
and glucose tolerance tests in Pima
Indians, 538-545, 546

and oral glucose tolerance tests,
585-591, 592-593
in dogs
and lipoprotein production from
endogenous lipid, 263-270
duration
and vascular disease prognosis, *606
education, *436
and electrical stimulation of vagus
and gastrin release, *693
and enzymes of glucose metabolism
and citrate cleavage pathway
in adipose tissue, 865-871
and ethanol ingestion
and glucose tolerance and insulin
secretion, *1128
and glucose tolerance, postglucose
hypoglycemia, and insulin
secretion, 933-942
etiology
and dietary-fiber-depleted starchy
foods, 762-764
and viruses, 1123-1124
in eviscerated rats with functioning
liver, *418
and foot problems, *435
and gangrene
superficial and deep wound cultures
and, *433
and glibenclamide
and gastrointestinal factors, *435
and glipizide pharmacokinetics, *437
and glomerulosclerosis
onset and progression of, 1-9
and glucagon, 523-524
and fatty acid metabolism,
1020-1025
and glucagon stimulation of
ketogenesis, *442
and glucose conversion to tri-
glycerides, *437
and growth hormone kinetics, 317-326
and growth hormone release-
inhibiting hormone, *56-57
and growth hormone response to
L-dopa
in diabetics and normals, 633-635
and hyperglycemia, *407
and hearing loss, *1126
hereditary and acquired, *310
and HL-A system, 345-349, *387
and hyperglycemia
and glucagon, *1033
and hyperglycemic hyperosmolar syn-
drome, 201-205
and hyperkalemia
and insulin sensitivity, *425
and hyperuricemia

and gout, *445
and hypoglycemia
and hyperthermia, 859-860
in identical twins
and histocompatibility antigens
study, *402
and metabolism and endocrine
studies, *385
and immune response, 772-773
incidence
and autoimmune thyroiditis,
829-832
and inhibition of labile aggregation-
stimulating substance and
platelet aggregation, 684-686
and insulin binding by hepatic plasma
membranes
and insulin therapy and calorie re-
striction, *394
and insulin binding to lymphocytes,
*606
insulin-deficient
and clofibrate suppression of
ketonemia, *442
and modulation of fatty acid
metabolism by glucagon,
510-515
insulin-dependent
etiology, *401
and pituitary responsiveness to
luteinizing hormone-
releasing hormone, 378-380
and insulin, diet, and sulfonylurea
therapy
and glucagon response to arginine,
811-818
and insulin and glucagon release
and arginine, 272-278
and insulin reserve, *432
and insulin secretion
and endogenous alpha-adrenergic
activity, *420
and insulin therapy
and unmeasured vs. conventional
diet, *425
and ischemia
and femoropopliteal and femoro-
tibial bypasses, *397
and femorotibial bypass, *1129
juvenile
and arginine and alanine stimulated
growth hormone release,
*401
and diazoxide and plasma renin ac-
tivity, 833-835
epidemiological analysis of, *427
epidemiological and virological
studies of, *386

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- and factitial panniculitis and necrotizing fasciitis, 856-858
 - and glucagon secretion in unaffected monozygotic twins of, *779
 - and growth hormone, glucagon and cortisol secretion and exercise, 758-761
 - and insulin-like insulinase-resistant material, 609-617
 - and islet-binding immunoglobulins, 230-236
 - long-term study, 559-564
 - and Mauriac syndrome, *242
 - and muscle capillary basement membrane changes, *400
 - non-insulin-dependent, heredity and, *402
 - and plasma lipid levels, diet and, 672-678
 - and renal transplantation and pregnancy, 497-501
 - and somatomedin deficiency, *407
 - and total and free plasma insulin levels, *447
 - juvenile-onset
 - and leukocyte chemotaxis in non-diabetic relative, *401
 - juvenile-onset and maturity-onset difference between inheritance of, 44-52
 - and viruses, *779
 - and ketone turnover, *406
 - and kidney collagen content, 1057-1064
 - and lactic acidosis
 - and phenformin, *428, *430
 - latent
 - and multiple aseptic bone necrosis, *389
 - treatment of, *443
 - management
 - and self-care, *688
 - maternal
 - and neonatal hypoglycemia, *411, *1035
 - and parathyroid function in infants, *1036
 - maturity-onset
 - and glibenclamide and chlorpropamide trials, *689
 - and glucagon levels and insulin-glucagon ratio, *434
 - and serum growth hormone levels, 977-981
 - and metabolic aberrations in non-diabetic offspring of diabetic parents, *433
 - and metabolism, 185-189
 - and microcirculation deterioration, 944-952
 - mild familial, *58
 - mild nonobese
 - and insulin response to glycemic stimulus, 17-26
 - and "monocomponent" pork insulin and antigenicity studies, 625-632
 - and myocardial infarction, *1036
 - and mortality, *309-310
 - and nonketotic hyperglycemic coma, 594-599
 - and pancreatitis, *388-389
 - pathogenesis
 - and glucagon, *607
 - and PEPCK ferroactivator, *416
 - and phenformin
 - and lactic acidosis, 791-799
 - and serum vitamin B-12 levels, *439
 - see also UGDP phenformin study in Pima Indians and Caucasians
 - and glucagon response to arginine, *427
 - and pituitary hormone function and pituitary irradiation, *395
 - and plasma glucose and glucagon levels
 - and somatostatin, *242, *308
 - and plasma renin activity, *414
 - and platelet aggregation, *428, *1035
 - with polyneuropathy,
 - hypothyroidism, and endocrine disturbances, *56
 - and porphyria cutanea tarda, *433
 - prevalence
 - in offspring of conjugal diabetic parents, 452-462
 - progesterone-induced in dog, 337-343
 - and pyruvate dehydrogenase, *415
 - and raw-food diet
 - and insulin requirements, *690
 - and renal failure
 - and plasma renin activity, *441
 - and renal papillary necrosis, *54
 - and renal substrate exchange, 730-733
 - research perspectives, 1123-1124
 - and resistance to ventromedial hypothalamus damage by gold thioglucose, *385
 - risk factors, *434
 - and sciatic nerve myelin content in rabbits, *397
 - screening
 - and quantitative urine glucose method, *430
 - in UGDP phenformin study, 69-70
 - and sexuality in females, *432
 - short-term
 - and chemical composition of glomerular basement membrane, *427
 - and somatostatin, 988-996
 - and "spontaneous" hypoglycemia and diagnosis of factitious hyperinsulinism, *1033
 - surveys
 - among male middle-aged civil service workers, *57
 - in Rochester, Minnesota, *440
 - and thalassemia major, *430
 - therapy
 - and cardiovascular disease prevention, *414
 - uncontrolled
 - and hemoglobin fraction, *415
 - and phagocytosis and microbicidal function, *426
 - and plasma renin activity and blood volume, 190-193
 - untreated
 - and insulin resistance, *396
 - and vascular disease
 - and red cell 2, 3-diphosphoglycerate levels, 724-728
 - and von Willebrand factor levels and platelet aggregation, *398
- DIALYSIS**
- peritoneal
 - and phenformin-induced lactic acidosis, 796
- DIAZOXIDE**
- and cataracts in dogs, 1041-1049
 - and plasma renin activity and juvenile diabetes, 833-835
 - and tumor hypoglycemia, *431
- DIBUTYRYL CYCLIC AMP**
- and alanine-U-¹⁴C incorporation into glucose, 650-656
 - and glycogen metabolism in human fetal liver, 1101-1111
- DIBUTYRYL CYCLIC GMP**
- and insulin biosynthesis, *403
- DICHLOROACETATE**
- and insulin metabolism and experimental diabetic ketoacidosis, *1032-1033
- DIET**
- carbohydrate intake and biphasic insulin response to intravenous glucose, 1072-1079

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

cholesterol and saturated fat restricted
and plasma lipid levels in juvenile
diabetics, 672-678
and diabetic pregnancy after renal
transplantation, 498
and fiber-depleted starchy foods
and diabetes development, 762-764
gluten-free
and Mauriac syndrome with villous
atrophy, *242, *308
high and low carbohydrate
and basal and postprotein insulin
and glucagon levels, 552-557
high-protein
and glucagon secretion, *409
high-sucrose feeding
and plasma triglyceride labeling,
*694-695
and hyperlipidemia, *692
and insulin secretion from rat
perfused islets, *436
and insulin sensitivity of adipose tis-
sue, 1088, 1089-1090
and latent diabetes, *443
and oral glucose tolerance tests
and psychiatric patients, *431
and phenformin effect on lipid trans-
port, *58
raw
and insulin requirements, *690
semistarvation
and weight reduction in obesity,
*690
therapy
and diabetes, and glucagon re-
sponse to arginine, 811-819
unmeasured vs. conventional
and insulin-treated diabetics, *425
and weight gain
and serum triiodothyronine, *406
and yeast
and glucose tolerance, *433
3, 5-DIMETHYLPYRAZOLE
-induced growth hormone release
and somatostatin, 843, 844
DIPHENYLHYDANTOIN
and sodium-potassium adenosine-
triphosphatase, *438
2, 3-DIPHOSPHOGLYCERATE
red cell
and pregnancy, *415
DNA
in isolated islets of neonatal rats,
747-748

synthesis
in isolated pancreatic islets, *1032
DOGS
alloxan diabetic
and exercise, methylprednisolone,
and glucose turnover,
915-920
and carbohydrate intake
and biphasic insulin response to in-
travenous glucose, 1072-1079
depancreatized
and insulin turnover and free fatty
acid studies, *525
depancreatized, alloxanized and
phloridzinized
and plasma glucagon, *412
and diazoxide
and cataracts, 1041-1049
and endotoxin shock
and hyperinsulinism, *398
and exsanguination and adrenergic
blockade
and plasma glucagon levels, 313-315
and gastric alpha cell function, *411
gastric inhibitory polypeptide study
in, 1050-1056
and gluconeogenesis regulation, *407
and hepatic glucose output
and glucagon and somatostatin and
insulin, *407
and hyperglycemia
and glucagon suppression of
somatostatin, *1033
insulin secretion
and cerebral intraventricular insu-
lin, 910-914
and intracisternal insulin
and plasma glucose and insulin,
905-909
pancreas
neural stimulation and glucagon
secretion studies, *439
and pancreas transplantation into
retroperitoneal jejunal loop,
*604
pancreatectomized
and endogenous lipid production
from intestine and liver,
263-270
progesterone-induced diabetes in,
337-343
and prostaglandin E₁
and insulin secretion, *58
and renal glucagon uptake, *387
and respiratory acidosis and alkalosis
and cerebrospinal fluid bicarbonate
regulation, *781

and sulfonylurea-stimulated insulin
secretion
and propranolol and ergot alkaloids,
*444
and vagal stimulation
and insulin and glucagon secretion,
*387

L-DOPA
growth hormone response to
and glucose, 633-635
and hyperglycemia, *407
-induced hypoglycemia
glucagon responses to, *411

E

ELECTRICAL ACTIVITY
and glucose and amino acid interac-
tions in rat pancreatic islets,
489-495

ELECTRICAL STIMULATION
of vagus
and gastrin release, *693

ELECTROCARDIOGRAPHS
in UGDP phenformin study, 96-98,
129

ELECTROLYTES
transport in brain
and hypoglycemic seizures and
coma, *241
and insulin, *307

ELECTROMYOGRAMS
and hyperuricemia and gout, *445

ELECTROPHORESIS
agar gel, 230
and hemoglobin of diabetics, *415
of islet-binding sera, 235-236
polyacrylamide gel
of monocomponent insulin, 627
and proinsulin messenger RNA, *405

ENDOCRINE GLANDS
disturbances
with plasma cell dyscrasia and
polyneuropathy, *56
and identical diabetic twins, *385

ENZYMES
and digestion of tendon collagen
and aging and diabetes, 902-904
of glucose metabolism and citrate

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

cleavage pathway
in adipose tissue of normal and
diabetic subjects, 865-871
glycolytic
and insulin resistance, *388

EPINEPHRINE
and heart glycogen synthetase and
phosphorylase activity,
*1128-1129
-induced hypoglycemia
glucagon responses to, *411
and insulin release induced by MAO
inhibitors, *1032
poisoning
and lactic acidosis, *691
-stimulated lipolysis
and insulin and proinsulin, 238-239

ERGOT ALKALOIDS
and sulfonylurea-stimulated insulin
secretion in dogs, *444

ESTROGEN
and serum cholesterol, *385

ETHANOL. See also Alcohol
administration
and blood acetaldehyde in alcoholics
and nonalcoholics, *691
and glucose-mediated insulin response
in rats, *440
and glucose tolerance and insulin se-
cretion
in diabetics and normals, *1128
hypoglycemia
turnover studies, *693
-induced alterations of glucose toler-
ance, postglucose hypogly-
cemia, and insulin secretion
in normal, obese, and diabetic sub-
jects, 933-942
-induced hypoglycemia
and glucagon secretion, 295-299
and isoproterenol-induced hyper-
glycemia, *57
and pancreatic islet monoamine ox-
idase, *432

EUTHYROID
and insulin metabolism, 923-924

EXERCISE
and adipocyte glucose metabolism
and insulin responsiveness, *57
and glucose turnover
and methylprednisolone in diabetic
dogs, 915-920

and growth hormone, glucagon, and
cortisol secretion
in obese and diabetic children,
758-761
marathon running
after myocardial infarction, *56
and pyruvate dehydrogenase, *415
and skeletal muscle substrate utiliza-
tion, *387-388
and weight reduction in obese women,
*1034

EXSANGUINATION
and plasma glucagon levels
and adrenergic blockade, 313-315

EXTREMITIES
diabetic changes, 946-947

**EYES. See also Retina, Retinopathy, Vi-
sion**
cataracts
and diazoxide, 1041-1049
examinations
in UGDP study, 100-103, 128

F

FAMILY HISTORY
and chemical diabetes in children and
adolescents, 753
of diabetes or cardiovascular diseases
in patients in UGDP study, 122
and diabetes and glucose intolerance
in offspring of conjugal diabetic par-
ents, 452-462
and diabetes mortality, *440
and HL-A antigens
and diabetes, 345-349
and hyperlipidemia management,
*692
and juvenile-onset and maturity-onset
diabetes in young people,
44-52
and leukocyte chemotaxis in relatives
of juvenile-onset diabetics,
*401

FASTING. See also Starvation
and PEPCK ferroactivator, *416

FAT(S)
absorption
and glucose-stimulated glucagon
and insulin secretion, *604
saturated
and plasma lipid levels in juvenile

diabetics, 672-678

FAT CELLS. See also Adipocytes
cyclic AMP accumulation, lipolysis
and glucose metabolism
and adenosine deaminase, *690
diameter
and body fat, 1091
and glucose analogue uptake
and size and intracellular water,
*431
isolated
insulin degradation by, 1011-1018
and lipolytic effects of insulin and
proinsulin, 238-239
size
and adenosine triphosphate levels,
*418
in pyelonephritic rats, 885-886

FATTY ACIDS
free
and acute myocardial infarction, *55
and insulin-glucagon interactions,
*525
and ketone production, 524
response to glucose in pyelonephrit-
ic rats, 885
and somatostatin, *526
in uncontrolled diabetes, 269
in lipoprotein triglyceride
source of, 266
metabolism
and glucagon, 502-508, 510-515,
1020-1025
odd-carbon
and ketosis and lipemia in pregnant
fasted rats, *445
synthesis by adipose tissue, *780

FEET
care
in elderly diabetic, *435

FEMOROPoplITEAL BYPASS
and ischemia, *397

FEMOROTIBIAL BYPASS
and ischemia, *397, *1129

FETUS
and insulin response to glucose, 291
islet beta cell and decreased glucose
excitation, *400
liver
and hormonal regulation of
alanine-U-¹⁴C incorporation
into glucose in, 650-656

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

and hormonal regulation of glycogen metabolism, 1101-1111, 1113-1122
 monkey
 and glucagon metabolism, *307
 rat
 and insulin biosynthesis, 373-376
 simian
 glucagon metabolism in, *241

FIBRINOLYTIC SYSTEM
 and diabetic retinopathy, 529-533

FIBROBLASTS
 and insulin binding studies, *441

FISHER EXACT TEST, 97, 110
 and mortality statistics, 74

FLUOROCORTISONE. *See*
 9-Alpha-fluorohydrocortisone

9-ALPHA-FLUOROXYDROCORTISONE
 and postural hypotension, 381-384

FRUCTOSE
 antiketogenic action of, 926-931

FRUCTOSE 1, 6-DIPHOSPHATASE
 deficiency
 and L-alanine tolerance tests, *604

FUNDUS ABNORMALITIES
 in UGDP phenformin study patients, 101-103

FUROSEMIDE
 -induced diuresis
 and phenformin-induced lactic acidosis, 796, 799

G

GAMMA GLOBULIN
 monoclonal
 and serum immunoreactive insulin, 214-223

GANGRENE
 and diabetes, *433

GASTRECTOMY
 and hypoglycemia
 and adrenergic agents, *412, 1005-1009

GASTRIC INHIBITORY POLYPEPTIDES
 endogenous
 and glucose tolerance, *413
 response to glucose
 and vagotomy and pyloroplasty, *389
 and responses to oral glucose by normals and diabetics, *413

GASTRIN
 release
 and electrical stimulation of vagus, *693
 response to insulin
 and vagotomy, *388

GASTROINTESTINAL SYSTEM
 and antidiabetic effect of glibenclamide, *435
 chylomicron-like lipoprotein production
 in pancreatectomized dogs, 263-270
 duodenal factors
 and glibenclamide, *413
 glucagon
 identification of, *1035-1036
 glucose absorption
 and ethanol ingestion, *1128
 glucose and lysine absorption, *243, *309
 hormones
 and cyclic AMP levels and amylase output in rat pancreas, *1033
 hyperglucagonemia and hyperglycemia, *428
 inhibitory polypeptides, *413
 intrajejunal administration of water-in-oil-in-water insulin emulsions
 and alloxan diabetes, 971-975
 jejunum function
 and glucagon, *605
 peritonitis
 and differential tissue sensitivity to endogenous insulin levels, *692
 and phenformin-associated lactic acidosis, 28, 29
 retroperitoneal jejunal loop pancreas transplantation into, *604
 vitamin B-12 absorption
 and phenformin therapy, *439

GEL FILTRATION
 and identification of glucagon in gastrointestinal tract, *1035-1036

GENETICS
 and heterogeneity
 and diabetes, 44-52

GLIBENCLAMIDE
 antidiabetic effect of
 and gastrointestinal factors, *435
 binding to pancreatic beta cells and albumin, *308
 and catecholamine release, *1034
 and stimulation of insulinogenic duodenal factors in rats, *413
 therapy
 in diet-failed, maturity-onset diabetes, *689

GLIPIZIDE
 pharmacokinetics
 and diabetes, *437

GLOMERULOSCLEROSIS, DIABETIC
 onset and progression of, 1-9

GLUCAGON
 activity
 and acquired and endogenous hyperlipemia, *604
 and alanine-U-¹⁴C incorporation into glucose, 650-656
 and amino acid and nitrogen metabolism
 and fasting, *54
 basal
 and gluconeogenesis, *407
 basal and postprotein
 and carbohydrate intake, 552-557
 and diabetes, 523-524, 1124
 and diabetes pathogenesis, *607
 endogenous
 and kidneys, *387
 and fatty acid metabolism in man, 1020-1025
 and free fatty acid metabolism, 502-508, 510-515
 and gluconeogenesis from alanine in normal postabsorptive man, 574-583
 and glycogen metabolism in human fetal liver, 1101-1111
 and growth hormone release-inhibiting hormone, *56-57
 and hyperglycemia in diabetes, *1033
 identification in gastrointestinal tract, *1035-1036
 immunoreactivity
 and chloramine-T, *1130
 and liver function, 637-640

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

in plasma of pancreatectomized patient, *411
 responses to intravenous tolbutamide in chronic pancreatitis, 851-855
 and insulin
 negative feedback for, *442
 and insulin biosynthesis
 in isolated pancreatic islets of newborn and fetal rats, 373-376
 -insulin protease
 and glucagon degradation, *426
 -insulin ratio
 and blood ammonia levels, *389
 and isoproterenol
 and glucose infusion, *446
 and jejunum function, *605
 and ketogenesis
 and diabetes, *442
 levels
 in maturity-onset diabetics, *434
 and prediabetes, *386
 and meal-induced gastric secretion, *780
 metabolism
 in pregnant monkeys, *241, *307
 pancreatic
 and glucose homeostasis, *780
 pancreatic and gut
 interactions with vasoactive intestinal polypeptide, liver and fat, *54
 and plasma alanine, glutamine metabolism, and hepatic gluconeogenesis
 in sheep, *1125
 plasma glucose and insulin responses to
 and somatostatin, *690
 and plasma lipoprotein lipase, *241, *307
 -propranolol stimulation
 and growth hormone and cortisol secretion, *58
 protective effect on isolated perfused rat heart after hypoxia, *689
 release
 amino-acid induced, and insulin and glucose, *692
 and arginine, 272-278
 from isolated rat islets of Langerhans, lectins and, 705-713
 and leucine, *410
 from perfused islets of Chinese hamsters with diabetic genotype and variable phenotype, *409

and somatostatin, 961-970
 and vagus nerve, *525
 response
 in non-diabetic offspring of diabetic parents, *433
 response to alanine
 and neurofibrosarcoma, *1128
 response to arginine
 and diabetes therapy, 811-818
 in prediabetic, diabetic and normal Pima Indians and Caucasians, *427
 response to L-Dopa, epinephrine, and insulin-induced hypoglycemia
 in normal and insulin-dependent diabetic, *411
 response to glucose
 in pyelonephritic rat, 885
 response to starvation and hyperglycemia
 and adrenergic blockade, *526
 secretagogues
 interactions with glucose secretagogues in perfused rat islets of Langerhans, *409
 secretion
 and alpha- and beta-D-glucose, 369-371
 arginine-stimulated acute phase, 735-739
 and ethanol-induced hypoglycemia, 295-299
 and exercise in obese and diabetic children, 758-761
 and high-protein diet, *409
 and hypertriglyceridemia and clofibrate treatment, *1130
 and intrapancreatic infusion of acetylcholine, *56
 and intravenous glucose administration, *604
 and lipids, *604
 in monozygotic twins of juvenile diabetics, *779
 and neural stimulation of isolated canine pancreas, *439
 scorpion toxin-induced, *409
 and somatostatin, *408
 spontaneous and amino acid stimulated, in infants of diabetic mothers, *411
 and tolbutamide, *410
 and vagal stimulation, *387
 sensitivity
 development in neonatal rat liver, *410
 and somatostatin

and glucose turnover, *408
 and somatostatin and insulin
 and liver glucose output in normal dogs, *407
 -stimulated growth hormone release and somatostatin, 846-847
 suppression
 in islets of normal and diabetic rats, *440

GLUCOCORTICOIDS
 and catecholamine-induced lipolysis, *1127-1128

GLUCONEOGENESIS
 and 2-deoxyglucose administration, *417
 and ethanol, *57
 and glucagon, *1125
 glucagon stimulation from alanine, 574-583
 and intravenous L-alanine tolerance test, *604
 and kidney, 730-733
 from lactate and intracellular pH in liver
 and phenformin, 618-623
 liver
 and insulin, *438
 regulation
 and basal insulin and glucagon, *407

GLUCOSE
 and amino acid
 interactions in rat pancreatic islets, 489-495
 and amino-acid-induced glucagon and insulin release, *526
 and amino-acid-induced glucagon release
 in isolated pancreas of diabetic rats, *692
 analogue uptake by fat cells
 and fat cell size and intracellular water, *431
 -anomeric specific insulin release, *404
 biphasic insulin response to
 and carbohydrate intake, 1072-1079
 control
 in UGDP patients, 133-153
 conversion to VLDL-triglycerides and diabetes, *437
 cyclic AMP and insulin response to
 in isolated islets of neonatal rats, 746-751
 excitation in fetal islet beta cell, *400
 gastric inhibitory polypeptide re-

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

sponse to
and vagotomy and pyloroplasty,
*389
gastrointestinal absorption of, *309
in children, *243
and glycogen synthase, *781
and growth hormone response to
L-dopa
in normals and diabetics, 633-635
homeostasis
and islet isografts, *419
and pancreatic glucagon, *780
and plasma glucagon and insulin in
pregnant rats, *607
and portal and peripheral insulin
administration, *404
incorporation of alanine-U-¹⁴C into
and hormones, 650-656
-induced hyperglycemia
and glucose dose and insulin, *441
-induced insulin release
and cyproheptadine, 836-841
and verapamil, 547-551
infusion
and glucagon and insulin responses
to isoproterenol, *446
ingestion
and splanchnic glucose and
gluconeogenic substrate
metabolism, 468-474
and insulin
and glycogen synthase system in
skeletal muscle of normal
humans and patients with
myotonic dystrophy, *242
and insulin biosynthesis
in isolated pancreatic islets of new-
born and fetal rats, 373-376
and insulin and glucagon release
from perfused islets and perfused
pancreas, 962-963
in pyelonephritic rats, 885
and insulin released from isolated is-
lets of Langerhans in long-
term organ culture, 658-662
insulin response to
and endogenous hyperlipopro-
teinemia without diabetes or
obesity, 209
and long-term propranolol therapy,
*55
in nonobese mild diabetics and
normals, 17-26
in premature infants, 291-293
and secretin, *438
-insulin substrate interrelationships
in neonatal sheep, *604-605
intolerance

and acute myocardial infarction, *55
in carcinoid syndrome, 664-670
and chemical diabetes in children
and adolescents, 755
insulin response during, *442
in offspring of conjugal diabetic par-
ents, 452-462
intravenous
and glucagon and insulin secretion
during fat absorption, *604
and plasma insulin removal rate,
*57
kinetics
and theophylline, 249-255
metabolism. *see* Glucose metabolism
oral
and gastric inhibitory polypeptide
responses in diabetics and
normals, *413
and insulin response and creatinine
clearance, 1066-1070
penetration
in islets of normal and diabetic rats,
*440
and proinsulin-insulin and protein
biosynthesis, 194-200
regulation
and glucagon, 523-524
response to
in non-diabetic offspring of diabetic
parents, *433
secretagogues
interactions with glucagon se-
cretagogues in perfused rat is-
lets of Langerhans, *409
serum immunoreactive insulin re-
sponse to
and gastric inhibitory polypeptide,
1050-1056
and somatostatin, 1124
-stimulated growth hormone release
and somatostatin, 846
-stimulated insulin release
anomeric specificity of, *690
and calcium, *1127
and glucose concentration rate of
change, *399
stimulation
and portal and peripheral blood
proinsulin, insulin and
C-peptide, *1034
and tolbutamine and insulin, 354-360
transport
into brain, *417
and concanavalin A and calcium,
*448
and dexamethasone, *393
transport in fat cells

and adenosine triphosphate levels,
*418
turnover
and exercise, in diabetic dog,
methylprednisolone and,
915-920
and insulin-glucagon interactions,
*525
and somatostatin, *408
utilization
and serum chromium, 350-352

GLUCOSE METABOLISM

adipocyte
and exercise, *57
compared with maltose metabolism,
*695
enzymes of, in adipose tissue of nor-
mal and diabetic subjects,
865-871
and ethanol hypoglycemia, *693
of fat cells, adenosine deaminase and,
*690
and hindlimb perfusions in normal and
diabetic dogs, *448
in pyelonephritic rats, 886
in rat pancreatic islets, 476-487
in small-for-gestational age infants,
*1036
and streptozotocin in obese hyper-
glycemic mice, *688
in thyroidectomized and normal dogs,
during rest and cold expo-
sure, *1035
and transport in brain, *1129
and traumatic brain injury, *691
in uremia
and serum calcium and parathyroid
hormone, *1125

GLUCOSE TOLERANCE

borderline
and prevention of cardiovascular
disease, *414
and ethanol ingestion
in normal and diabetic subjects,
*1128
in normal, obese, and diabetic sub-
jects, 933-942
and gastric inhibitory polypeptides,
*413
and hemodialysis
and chronic renal failure, *693-694
and hyperinsulinemia and hypoin-

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- sulinemia study, 362-367, 368
 and insulin secretion
 and parathyroid disorders, *1037
 and protein-calorie malnutrition, *444
 in Toubou Broayas, 983-986
 and yeast, *433
- GLUCOSE TOLERANCE FACTOR**
 and glucose and lipid levels, *446
- GLUCOSE TOLERANCE TESTS**
 and autoimmune thyroiditis, 829-832
 in children and adolescents
 and age-adjusted analysis of insulin
 responses during, 820-827
 and diabetes with Bell's palsy, 450
 and diabetes diagnosis in Pima Indians
 and one- and two-hour glucose
 levels, 538-545, 546
 and diabetes survey among male
 middle-aged civil servants,
 *57
 and diabetes therapy, 813
 and early insulin response, 17-26
 and hypoglycemia
 and insulinoma, 535
 in metabolism studies with C-glucose,
 186
 in offspring of conjugal diabetic par-
 ents, 452-462
- oral
 and capillary basement membrane
 width, in prospective related
 kidney donors, *434
 and diabetes diagnosis, 2
 and diet, *431
 evaluation problems with, 585-593
 and porphyria cutanea tarda, *433
 and potential diabetics, *310
 reevaluation of, *445
 three-hour oral
 and detection of hyperglycemia and
 hypoglycemia in pregnancy,
 874-880
 in UGDP study, 69-70, 123, 124
 mean values and standard errors,
 171
 and uremia
 and immunoreactive insulin, *437
- GLUCOSE-¹¹C**
 and brain glucose transport and
 metabolism measurement,
 *1129
- ¹³C-GLUCOSE**
 naturally labeled
- and metabolism studies in diabetes
 and obesity, 185-189
- D-GLUCOSE**
 alpha and beta
 differential effect on insulin and
 glucagon secretion, 369-371
 alpha and beta anomers of
 and insulin secretion, *690
 anomers
 and alloxan, insulin biosynthesis and
 secretion and, *404
 insulin secretion by, *526
- GLUCOSE-6-PHOSPHATASE**
 and thyroid state in rats, *688
- GLUTAMINE**
 and glucagon infusion in fasted man,
 *54
 metabolism
 and glucagon, *1125
- GLUTAMINE SYNTHETASE**
 and diabetes, *416
- GLYBURIDE**
 and antidiuretic response in pituitary
 diabetes insipidus, *526
- GLYCERALDEHYDE**
 antiketogenic action of, 926-931
 and arginine-induced insulin and
 glucagon release
 in perfused islets and perfused pan-
 creas, 964-965
- D-GLYCERALDEHYDE**
 and insulin release, *403
- GLYCERALDEHYDE 3-PHOSPHATE
DEHYDROGENASE**
 inhibition by plasma and serum, *1129
- GLYCOGEN**
 and amino acid incorporation into
 protein
 and insulin, *447
 and insulin action, *1034-1035
 metabolism
 in human fetal liver, 1101-1111,
 1113-1122
 in muscle, *1129
 rat liver content of
 and thyroid state, *688
 synthesis
 and adipocytes, 1088-1089
- GLYCOGEN SYNTHASE**
 and glucose as acceptor, *781
 and glucose and insulin, *242
 heart
 and insulin and epinephrine, *1128
 in human fetal liver, 1113-1122
 in isolated hepatocytes
 and insulin, acetylcholine,
 bethanechol and atropine,
 *425
 in skeletal muscle of normal humans
 and patients with myotonic
 dystrophy, *308-309
- GLYCOGEN SYNTHASE D PHOS-
PHATASE**
 in heart
 and insulin, *394
- GLYCOGENESIS**
 and insulin, acetylcholine,
 bethanechol and atropine,
 *425
 and insulin action, *394
- GLYCOPROTEINS**
 and diabetes, 1124
- GLYCOSURIA**
 after kidney transplantation, *55-56
- GOLD THIOGLUCOSE**
 damage to ventromedial hypothalamus
 and diabetes-induced resistance,
 *385
- GONADOTROPIN**
 secretion
 and diabetes, 378-380
- GOUT**
 and glucose tolerance
 and electromyograms, *445
- GRANULOCYTES**
 and insulin receptor studies, *393
 and poorly controlled diabetes, *426
- GRAVES' DISEASE**
 and HL-A antigens, *387
- GROWTH**
 failure
 and somatomedin, *407
- GROWTH HORMONE**
 binding studies, *309
 deficiency

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

and development of obese-hyperglycemic syndrome in mice, *1127
and hypopituitarism, 1029-1030
and insulin, *525
kinetics
and diabetes, 317-326
and pancreatic and serum insulin and blood glucose, *688
release
and arginine and alanine, *401
and hypothalamic surgery and somatostatin, *691
response
and prediabetes, *386
response to L-dopa
and glucose, 633-635
and hyperglycemia, *407
secretion
and exercise in obese and diabetic children, 758-761
and free fatty acids, *604
and nephrotic syndrome, *1033
and propranolol-glucagon testing, *58
and somatostatin, acromegaly and, 842-849, *1033-1034

GROWTH HORMONE RELEASE-INHIBITING HORMONE
and circulating glucagon, insulin, and growth hormone, *56-57
radioimmunoassay, *779

GUANOSINE-TRIPHOSPHATE
-binding sites in myocardium
and adenylate cyclase activity, *780

GUINEA PIGS
and cortisone
and islet cell neogenesis, *447

H

HAMSTERS. *See* Chinese golden hamsters

HARTNUP DISEASE, *1128

HEARING
impaired
and diabetic neuropathy, *1126

HEART. *See also* Cardiovascular disease examinations
in UGDP phenformin study, 92-100

glycogen synthase D phosphatase
and insulin, *394
glycogen synthetase and phosphorylase activity
and insulin and epinephrine, *1128-1129
and hormone action studies
and isolated rat heart cells, *429
muscle
insulin receptors in, 715-722
and protein turnover and insulin, *780
and protective effects of glucagon, *689
rates
of UGDP phenformin study patients, 99-100, 130, 173

HEART DISEASE. *See also* Cardiovascular disease
acute myocardial infarction and acute coronary insufficiency
and serum glucagon and insulin levels and blood glucose, *694
cardiomyopathy
and diabetes, *242
coronary
and cholesterol-altering drugs, *385
and diabetes, *691
and long-term juvenile diabetics, 562
myocardial infarction
and diabetes, *309-310, *1036

HEMODIALYSIS
and diabetes with chronic renal failure, *1128
and glucose tolerance
and renal failure, *693-694
and phenformin-associated lactic acidosis, 33

HEMOGLOBIN
"fast"
and pregnancy, *415
in uncontrolled diabetes, *415

HEMOLYSIS
and streptozotocin, *399

HEPATECTOMY
and dichloroacetate and insulin interactions
in experimental diabetic ketoacidosis, *1032-1033

HEPATOCYTES
isolated rat
and insulin binding and dexamethasone, *1129

HEREDITY
and decreased glucagon activity
and hyperlipemia, *604
and diabetes
and HL-A antigens, 345-349, *387
and diabetes and glucose intolerance in offspring of conjugal diabetic parents, 452-462
and diabetic genotypes and variable phenotypes
and insulin and glucagon release, *409
and juvenile-onset and maturity onset diabetes in young people, 44-52
and juvenile-onset non-insulin dependent diabetes, *402
and leukocyte chemotaxis in nondiabetic relatives of juvenile-onset diabetics, *401
and mild familial diabetes, *58
and monozygotic twins of juvenile diabetics
and glucagon secretion studies, *779
and non-diabetic offspring of diabetic parents, *433
and proinsulinemia, *413

HL-A ANTIGENS
and diabetes, 345-349, *387

HORMONES
altered patterns
and diabetes, 952
enteric
autonomic control of, *693
gastrointestinal
and cyclic AMP levels and amylase output in rat pancreas, *1033
growth hormone release-inhibiting, *56
radioimmunoassay for, *779
and hypoglycemia, *412
immunoreactive parathyroid
and alloxan diabetes, *58
and incorporation of alanine-U-¹⁴C into glucose, 650-656
luteinizing hormone-releasing hormone, pituitary responsiveness to, in diabetics, 378-380
and obesity treatment, *606

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- peptide
transport across isolated rat mesen-
tery, 997-1004
- pituitary
and pituitary irradiation in diabet-
ics, *395
- progesterone
and induced diabetes in dogs,
337-343
- and rat heart cells, *429
- serum parathyroid
and glucose metabolism in uremia,
*1125
- serum polypeptide
immunoassay, *779
- substrate relationships
and trauma, *691-692
- HYPERCHOLESTEROLEMIA**
and diabetic retinopathy, 531
- HYPERGLUCAGONEMIA**
after burns, *694
in nonketotic hyperosmolar coma, *56
shock-induced
and adrenergic blockade, 314-315
- HYPERGLYCEMIA**
and alcoholic ketosis, 788
development in healthy subjects, *402
and diabetes
and glucagon, *1033
in diabetic *Macaca nigra*, 204
fasting
and traumatic brain injury, *691
and untreated diabetes and insulin
resistance, *396
glucagon responses to
and adrenergic blockade, *526
and glucagonemia, 523-524
glucose-induced
and glucose dose and insulin
studies, *401
and growth hormone response to
L-Dopa
and diabetes, *407
isoproterenol-induced
and insulin, *57
after kidney transplantation, *55-56
and leucine incorporation into protein,
196-197
nonketotic
and stupor, 594-599
in obese mice
and streptozotocin, *688
and phenformin-associated lactic
acidosis, 32
- in pregnancy
and three-hour oral glucose toler-
ance test, 874-880
and theophylline, 249-255
in UGDP study, 67
and ventromedial hypothalamic nu-
cleus stimulation, *386
- HYPERINSULINISM**
in endotoxin shock dogs, *398
factitious
plasma C-peptide in diagnosis of,
*1033
and glucose tolerance, 362-367, 368
and hyperlipoproteinemia
without diabetes, 207-212
and hypoglycemia
and neurofibrosarcoma, *1128
and insulin-sensitive glucoregulator
receptor, 329-335
and insulin sensitivity, *432
- HYPERKALEMIA**
and diabetes
and insulin sensitivity, *425
- HYPERLIPEMIA**
and decreased glucagon activity
and heredity, *604
- HYPERLIPIDEMIAS**
management, *692
- HYPERLIPOPROTEINEMIA**
without obesity or diabetes
and hyperinsulinemia and enlarged
adipocytes, 207-212
type III
and lipoprotein studies, *387
type IV
and multiple aseptic bone necrosis,
*389
- HYPEROSMOLAR DIABETIC SYN-
DROME**
experimental
and ketogenic response to
medium-chain triglycerides,
301-305
- HYPERPARATHYROIDISM**
and glucose tolerance tests, *1037
- HYPERTENSION**
and arteriosclerosis
and diabetic retinopathy, *435
and cardiovascular disease
and plasma renin activity, *429
and diabetes
and vascular disease, *606
and plasma renin activity, 833
in UGDP phenformin study patients,
94-96
- HYPERTHERMIA**
and hypoglycemia
and diabetes duration, 859-860
- HYPERTHYROIDISM**
and identical diabetic twins, *385
- HYPERTRIGLYCERIDEMIA**
carbohydrate induced, *416
and carbohydrate intolerance
in childhood obesity, *439
and hepatic steatosis and plasma insu-
lin levels, *1128
and insulin deficiency, 263
and lipid transport
and phenformin, *58
primary endogenous
and glucagon secretion and clofi-
brate treatment, *1130
- HYPERURICEMIA**
and glucose tolerance
and electromyogram, *445
- HYPOALDOSTERONISM**
hyporeninemic
and insulin sensitivity, *425
- HYPOGLYCEMIA**
and central nervous system
glucoregulator receptor
study, 329-335
"chemical," *54
and chlorpropamide, *396
L-Dopa, epinephrine and insulin-
induced
glucagon responses to, *411
endotoxin-induced
and hyperinsulinism, *398
ethanol-induced
and glucagon secretion, 295-299
and ethanol
turnover studies in man, *693
and hyperinsulinemia
and neurofibrosarcoma, *1128
and hyperthermia
and diabetes duration, 859-860
idiopathic reactive

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

and probantheline treatment, *425
and insular hyperplasia, *243
insulin-induced
and juvenile diabetes, 561
in pregnant monkeys, *241
in latent diabetes
and acetohexamide, *443
and malignant insulinoma
and ectopic ACTH syndrome,
600-603
neonatal, *411
and hepatic glycogen, 1101
in infants of insulin-dependent
diabetic mothers, *1035
non-humoral tumor
and oral diazoxide, *431
C-peptide, proinsulin and insulin re-
sponses to
and diagnosis of insulinomas, *412
postgastrectomy
and adrenergic agents, *412,
1005-1009
postglucose
and ethanol in normal, obese, and
diabetic subjects, 933-942
in pregnancy
and three-hour oral glucose toler-
ance tests, 874-880
and propranolol therapy
and insulinoma, 535-537
and pulmonary edema, *426
and seizures and coma, *241, *307
substrate and hormonal responses to,
*412
sympathetic control of hepatic
glycogenolysis and, *1129
in UGDP study, 91

HYPOINSULINEMIA
and glucose tolerance, 362-367, 368

HYPOPARATHYROIDISM
and glucose tolerance tests, *1037

HYPOPITUITARISM
anterior
and diabetic complications,
1027-1030
and growth hormone release-inhibit-
ing hormone, *56-57

HYPOTENSION
postural
and 9-alpha-fluorohydrocortisone,
381-384

HYPOTHALAMO-HYPOPHYSEAL-

**ADRENOCORTICAL SYS-
TEM**
and alloxan diabetes in rats, *242,
*308

HYPOTHALAMUS
islet-stimulating factor
in monkeys, *436
surgery
and chlorpromazine-induced
growth hormone release in
rats, *691
ventromedial
resistance to gold thioglucose dam-
age, *385

HYPOTHYROIDISM
and insulin metabolism, 922-925
with plasma cell dyscrasia and
polyneuropathy, *56
and rat liver glucose-6-phosphatase ac-
tivity and glycogen content,
*688

HYPOXIA
and glucagon effects on isolated per-
fused rat heart, *689
and red cell 2, 3-diphosphoglycerate
levels, 724

I

IMMUNITY
cell-mediated
and diabetes, 36-43

IMMUNOGLOBULINS
islet-binding, 230-236
renal clearance
and diabetic retinopathy, *436

IMMUNOGLOBULINEMIA
monoclonal
and serum immunoreactive insulin
levels, 204-223

IMMUNOPEROXIDASE METHOD
and human serum globulin binding to
islet tissue, 230-236

IMMUNOSUPPRESSION
and tumor growth, *243

INFANTS
of diabetic mothers

and glucagon secretion studies,
*411
and maternal macroseмия, *439
and neonatal hypoglycemia, *1035
and parathyroid function, *1036
premature
and insulin response to glucose
priming, 291-293
small-for-gestational-age
and oral alanine, *1036

INFECTION

Coxsackie B-4 virus
and juvenile diabetes, *386
and glucose utilization
and serum chromium, 350-352
and insulin antagonism
and pyelonephritis, 881-889
and pancreatic abscess, *605
and poorly controlled diabetes, *426

INSULIN

absorption
and insulin resistance, *443
and acetylcholinesterase and choline
acetylase
and sciatic nerve ligation in rats,
1081-1084
action, *1034
action
and glycogen, *1034-1035
and adipose tissue insulin receptors,
*394
and alcoholic ketosis, 788
allergy
and factitial panniculitis, 856-858
and alpha-cell response to hypo-
glycemia, 298-299
and amino acids incorporation into
protein and glycogen, *447
and amino-acid-induced glucagon re-
lease
in isolated pancreas of diabetic rats,
*692
antagonism
and brain injury, *691
in pyelonephritic rat, 881-889
basal
and gluconeogenesis, *407
basal and postprotein
and carbohydrate intake, 552-557
"big, big," 214-223
binding
by cultured fibroblasts from normal
subjects, *441
and dexamethasone, *393

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

and insulin therapy and caloric restriction in diabetic rats, *394
and receptor defects in obesity, *393
binding to isolated rat hepatocytes and adipocytes
and dexamethasone, *1129
binding to lymphocytes
and diabetes, *606
and obesity, *688
binding to receptors
and obesity, *688
binding studies, *309
biosynthesis, *693
and acetylcholine and cyclic GMP, *403
in isolated pancreatic islets of fetal and newborn rats, 373-376
and calcium binding to adipocyte plasma membranes, *395
cerebral intraventricular
and pancreatic insulin secretion in dog, 910-914
and cyclic nucleotide phosphodiesterase, *444
-deficient diabetes
and clofibrate suppression of ketonemia, *442
deficiency
and fatty acid metabolism and glucagon, 510-515
and hypertriglyceridemia, 263
degradation
by isolated fat cells, 1011-1018
by isolated rat liver cells, 566-572
dependency
and pituitary responsiveness to luteinizing hormone-releasing hormone, 378-380
-dependent diabetes
with autoimmune disease, and antibodies to pancreatic islet cells, *606
and dichloroacetate
and experimental diabetic ketoacidosis, *1032-1033
dosage
and diabetic ketoacidosis, *396
new time sequence for, *426
in pregnant juvenile diabetic after renal transplantation, 497-501
and electrolyte transport in brain
and hypoglycemic seizures and coma, *241, *307
endogenous levels
tissue sensitivity to, peritonitis and, *692

exogenous
and diabetes control, *401
fish
and diagnosis of insulinoma, *243
gastrin response to
and vagotomy, *388
and glucagon
and glucose turnover and free fatty acid concentrations in dogs, *525
negative feedback for, *442
-glucagon protease
and glucagon degradation, *426
-glucagon ratio, *310
and blood ammonia levels, *389
in maturity-onset diabetics, *434
and glucagon and somatostatin
and liver glucose output in normal dogs, *407
and gluconeogenesis regulation
in isolated hepatocytes from fed rats, *429
and glucose-induced hyperglycemia, *441
glucose-mediated response to
and ethanol in rats, *440
glucose substrate interrelationships
in neonatal sheep, *604-605
and glycogen metabolism in human fetal liver, 1101-1111
and glycogen synthase and glycogenesis, *425
and glycogen synthase system in skeletal muscle
and myotonic dystrophy, *242
and glycogenesis, *394
and growth hormone patterns, *525
and heart glycogen synthetase and phosphorylase activity, *1128-1129
and hepatic gluconeogenesis, *438
immunoreactive
and liver function, 637-640
and oral glucose tolerance test and uremia, *437
and somatostatin decreases in and glucose turnover, *408
-induced hypoglycemia
glucagon responses to, *411
in pregnant monkeys, *241
injections
cancer at site of, *431
insensitivity
in large rat adipocytes, *418
intracisternal
and plasma glucose and insulin in dog, 905-909

from islets of Langerhans in long-term culture
and glucose and anti-insulin serum, 658-662
and isoproterenol
and glucose infusion, *446
and ketoacidosis therapy, *385-386
and kidney function
and sodium, potassium, calcium, and phosphate, *1126
-like insulinase-resistant material
and juvenile diabetes, 609-617
and lipolysis in isolated fat cells, 238-239
lymphocyte transformation by
in insulin-treated and newly diagnosed diabetics, 36-43
messenger RNA
isolation of, *405
metabolism
in chronic uremia and anephric state, *606
and hypothyroidism, 922-925
and mitochondrial metabolism, *242-243
"monocomponent" pork
antigenicity in diabetics, 625-632
multiple daily injections
and diabetic retinopathy, *397
and peripheral motor nerve conduction velocity
in streptozotocin diabetes, *1126
portal and peripheral administration
and glucose homeostasis, *404
and massive obesity, *447
of normals, *1034
proinsulin conversion to
hereditary defect in, *413
and protein turnover in heart muscle, *780
receptors
of adipocytes, *395
evolutionary stability of, *393
and granulocytes, *393
in heart muscle, 715-722
and insulin and cortisol, *394
at ultrastructural level, *395
release
and alloxan, *405
and antidepressant drugs, *1032
and arginine, 272-278
and calcium, 1123, *1127
glucose anomeric specific, *404
and glucose concentration rate of change, *399
glucose-stimulated, *690
and D-glyceraldehyde, *403

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- and growth hormone release-inhibiting hormone, *56-57
- to intravenous glucose, *402
- and islet-stimulating factor in monkey lateral hypothalamus, *436
- isolated beta granules model of, *1035
- from isolated rat islets of Langerhans, lectins and, 705-713
- and microtubular-microfilamentous system, *694, 892-900
- from perfused islets of Chinese hamsters with diabetic genotype and variable phenotype, *409
- and serum calcium, *1037
- and somatostatin in islets isolated with collagenase and isolated perfused pancreas, 961-970
- and sulphydryl-binding reagents, *310
- and verapamil, 547-551
- removal
 - by perfused rat liver, *692
- requirements
 - after cesarean section in diabetic patients, *605
 - and raw diet, *690
- reserve
 - and diabetes, *432
- resistance
 - and burns, *446
 - and experimental shock in rats, *55
 - and impaired insulin absorption, *443
 - in untreated diabetics with fasting hyperglycemia, *396
- response
 - and adenosine triphosphate content of isolated fat cells, *418
 - and glucose intolerance, *442
 - and streptozotocin in obese hyperglycemic mice, *688
 - to oral carbohydrate, 362-367, 368 and uremia, *1125
 - response to glucose
 - in isolated islets of neonatal rats, 746-751
 - in premature infants, 291-293
 - in pyelonephritic rat, 885
 - response to glucose and arginine and secretin, *438
 - response to glycemic stimulus
 - in nonobese mild diabetics and normals, 17-26
 - response to intravenous glucose
 - and carbohydrate intake, 1072-1079 and propranolol, *55
 - response to oral glucose
 - and creatinine clearance, 1066-1070 and endogenous hyperlipoproteinemia without diabetes or obesity, 209
 - in prediabetics, *1036
 - responses
 - in age-adjusted glucose tolerance tests in children and adolescents, 820-827
 - and exercise, *57
 - and prediabetes, *386
 - saline-bicarbonate therapy
 - and amino acid levels in diabetic ketoacidosis, 463-467
 - secretion
 - alloxan inhibition of, methylxanthines and cytochalasin B and, *400
 - and alpha- and beta-D-glucose, 369-371
 - arginine-stimulated acute phase of, 735-739
 - and carcinoid syndrome, 664-670
 - cobalt inhibition of, *1127
 - and colchicine, *443
 - and cyproheptadine, 836-841
 - and endogenous alpha-adrenergic activity, *420
 - and ethanol, 933-942
 - and ethanol ingestion, diabetes and, *1128
 - feedback regulation of, *403
 - by D-glucose anomers, *526
 - and intrapancreatic infusion of acetylcholine, *56
 - and intravenous glucose administration *604
 - from isolated perfused liver containing islet isografts, *419
 - and mild familial diabetes, *58
 - and nephrotic syndrome, *1033
 - neurally mediated alteration of, *403
 - in obese prediabetics, *445
 - and obesity and diet, *436
 - and parathyroid disorders, *1037
 - and pentose phosphate shunt, *427
 - and phenformin, *432
 - and phosphoinositide metabolism, *399
 - and prostaglandin E₁, *58
 - and protein-calorie malnutrition, *444
 - and somatostatin, *408
 - and somatostatin, acromegaly and, *1033-1034
 - in spiny mice, 1094-1100
 - sulfonylurea-stimulated, propranolol and ergot alkaloids and, *444
 - and vagal stimulation, *387
 - and vesicular binesis in beta cells, *398
 - sensitive glucoregulator center, 328-335
 - in central nervous system, *417
 - sensitivity
 - and diabetes with hyperkalemia, *425
 - and hyperinsulinism, *432
 - of isolated perfused rat liver, 225-229
 - of large human adipocyte in vitro, 1086-1092
 - serum-bound
 - and peptide hormone transport across isolated rat mesentery, 997-1004
 - serum immunoreactive
 - and monoclonal immunoglobulinemia, 214-223
 - and sodium retention, 645-648
 - and somatostatin
 - and acromegaly, *526
 - stimulated heart glycogen synthase D-phosphatase, *394
 - suppression of insulin secretion, *403
 - synthesis
 - by pancreatic islets after glucose exposure, 194-200
 - therapy
 - and glucagon response to arginine, 811-818
 - and insulin binding by hepatic plasma membranes from diabetic rats, *394
 - and mortality in UGDP study, 136, 147-152
 - and myocardial infarction, *1036
 - and phenformin-associated lactic acidosis, 28-33
 - and UGDP study life tables, 155-160
 - and unmeasured vs. conventional diet, *425
 - and tolbutamide and glucose, 354-360
 - treatment
 - and glycolytic enzymes, *388
 - water-in-oil-in-water emulsions

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

intrajejunal administration of, 971-975

¹²⁵I-INSULIN
 binding and degradation to isolated rat hepatocytes and liver membranes, 801-809
 binding to granulocytes, *393
 binding to plasma membrane fraction of rat and mouse myocardium, 715-722
 and insulin degradation by fat cells study, 1012-1018
 placental barrier to
 in insulin-dependent diabetics, *605

INSULINASE, 776-777
 -resistant material
 in juvenile diabetics, 609-617

INSULINOMAS
 diagnosis of, *412
 by suppression tests, *243
 and hypoglycemia
 and propranolol therapy, 535-537
 malignant
 and ectopic ACTH syndrome, 600-603

IODOACETATE
 and glycolysis
 and islets, 478-479
 and islet electrical responses to glucose
 and isoleucine, 492-493
 and L-isoleucine stimulation of glycolysis, 482

ISCHEMIA
 and diabetes
 and femoropopliteal and femorotibial bypasses, *397
 of lower extremity
 and femorotibial bypass, *1129

ISLETS OF LANGERHANS. See also
 Pancreas, islets; Isografts
 in bovine pancreas, *421
 isolated rat
 and lectins and hormone release, 705-713
 long-term culture, *421
 effect of glucose and anti-insulin serum or insulin released from, 658-662
 membrane potential studies, *387
 perfused rat

and interactions between glucose and glucagon secretagogues, *409
 transplantation
 and histocompatibility system, 766-775
 and vagal control of glucagon release, *525

ISOGRAFTS
 intraportal, *420
 islet
 intrahepatic portal vein, *419
 intraperitoneal, *419
 in perfused liver, *419
 and reversal of alloxan diabetes, *420

ISOLEUCINE
 and insulin secretion and biosynthesis, 197, 198

L-ISOLEUCINE
 and glucose
 and islet cell membrane potentials, 490-493
 and glycolysis, 482-483

ISOPROTENERENOL
 glucagon and insulin responses to
 and glucose infusion, *446
 -induced hyperglycemia
 and ethanol, *57
 and protein turnover and amino acid release
 in perfused skeletal muscle, *416

ISOTRANSPLANTATION
 of organ cultured neonatal pancreases
 and alloxan diabetes, *435

J

JEJUNUM
 and administration of water-in-oil-in-water insulin emulsions
 and alloxan diabetes, 971-975
 function
 and glucagon, *605

K

KETAMINE ANESTHESIA
 and systemic hypoglycemic response, 329-335

KETOACIDOSIS, DIABETIC
 absence in experimental hyperosmolar diabetic syndrome, 301-305
 experimental
 and insulin and dichloroacetate interactions, *1032-1033
 and hyperglycemia
 and hyperglucagonemia, 525
 and insulin dosage, *396
 and lactic acidosis, *430
 and plasma and cerebrospinal fluid amino acid levels, 463-467
 and plasma renin activity and blood volume, 190-193
 treatment
 and insulin infusion, *385-386

KETOGENESIS
 and glucagon
 and diabetes, *442

KETONE BODIES
 and antiketogenic action of fructose, glyceraldehyde, and sorbitol
 in rat, 926-931
 regulation
 and glucagon, 524
 renal conservation
 and starvation, *606-607
 splanchnic release, *525
 turnover
 and diabetes, *406

KETONEMIA
 and clofibrate
 and insulin-deficient diabetes, *442

KETOSIS
 alcoholic, 785-790
 in pregnant fasted rats
 and odd-carbon fatty acids, *445
 starvation and
 development of, 10-16

KIDNEYS
 biopsy
 and diabetes with anterior hypopituitarism, 1029
 and diabetic glomerulosclerosis study, 1-9

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

chronic uremia and anephric state
and insulin metabolism and dialysis,
*606
cortical phosphoenolpyruvate carbox-
ylase
and acid-base status in diabetic rat,
*525-526
creatinine clearance
and insulin response to oral glucose
loading, 1066-1070
and endogenous glucagon in dog, *387
examinations
in UGDP study, 103-104
failure
and diabetes and plasma renin activ-
ity, *431
and hemodialysis in diabetics, *1128
and hemodialysis, glucose tolerance
and, *693-694
function
and diabetes, 946
and phenformin therapy, 743-744
glomerular basement membrane
chemical composition of, *427
glomerular basement membrane
synthesis
and streptozotocin diabetes, *429
glomerular lesions
and pancreatic islet transplantation,
280-285
glomerular mesangial cell
and diabetes, 1124
glomerulus
collagen content, diabetes and,
1057-1064
of diabetic dog, 340-343
and ketone body conservation
and starvation, *606-607
lesions
and islet transplants, 774
mechanisms
and insulin, *1126
nephrotic syndrome
and insulin and growth hormone
secretion, *1033
papillary necrosis, *54
protein clearance
and diabetes and retinopathy, *436
pyelonephritis in rats
and metabolism studies, 881-889
and sodium retention
and insulin therapy in
streptozotocin-diabetic rats,
645-648
substrate exchange
and diabetes, 730-733
transplantation

and diabetic pregnancy, 497-501
and glycosuria and hyperglycemia,
*55-56
and oral glucose tolerance and capil-
lary basement membrane
width in related prospective
donors, *434

L

LABILE AGGREGATION- STIMULATING SUB- STANCE

inhibition of
and diabetes, 684-686

LACTATE

formation
by isolated islets, 477-478
in isolated perfused guinea pig liver
effect of phenformin on
gluconeogenesis from,
618-623

¹⁴C L-LACTATE

and phenformin and lactic acidosis
study, 741-744

LEAST SQUARES ESTIMATES, 77

in UGDP study, 165-166

LECTINS

and hormone release from isolated rat
islets of Langerhans, 705-713

LESCH-NYHAN DISEASE, *1128

LESIONS

glomerular
in diabetic rats treated with pan-
creatic islet transplantation,
280-285
onset and progression of, 1-9

LEUCINE

and glucagon release, *410
metabolism
and redox potential, *415

³H-LEUCINE

incorporation into protein, 194-200

LEUKEMIA

and immunosuppression

and adenocarcinoma of pancreas,
*243

LEUKOCYTE(S)

chemotaxis
in nondiabetic relatives of juvenile-
onset diabetics, *401

LIKELIHOOD APPROACH, 75-77

LIPEMIA

in pregnant fasted rats
and odd-carbon fatty acids, *445

LIPID(S)

endogenous
production of chylomicron-like
lipoproteins from, 263-270
and glucagon secretion, *604
transport
and phenformin, *58

LIPOLYSIS

and adenosine, *428
and adenosine deaminase, *690
catecholamine-induced
and glucocorticoids, *1127-1128
and glucagon, *241
of isolated fat cells
and insulin and proinsulin, 238-239
in pyelonephritic rats, 886-887

LIPOPROTEIN(S)

chylomicron-like
production from endogenous lipid
by intestine and liver of
diabetic dogs, 263-270
and hyperlipoproteinemia type III,
*387
very-low-density
glucagon control of, *604

LIPOPROTEIN LIPASE

and glucagon, *307
in rat skeletal muscle, *417

LIVER

alanine
and insulin, *438
cirrhosis
and blood ammonia levels during
elevation of insulin-glucagon
ratio, *389
chylomicron-like lipoprotein produc-
tion
in pancreatectomized dogs, 263-270

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

disease
and porphyria cutanea tarda, *433
in eviscerated rats
and acute diabetes, *418
function
and phenformin-induced lactic acidosis, 797-798
and plasma immunoreactive insulin and immunoreactive glucagon, 637-640
and glucagon stimulation of gluconeogenesis from alanine, 574-583
gluconeogenesis
and glucagon, *1125
and glucagon infusion in fasted man, *54
and insulin, *438
glucose output in normal dogs and somatostatin, glucagon, and insulin, *407
glucose-6-phosphatase activity and glycogen content
and thyroid state, *688
glycogen synthase, phosphorylase and glycogen
and prostaglandin E, *430
glycogenolysis
sympathetic control during glucopenia, *1125
human fetal
and glycogen synthase, 1113-1122
and hormonal regulation of glycogen metabolism, 1101-1111, 1113-1122
isolated hepatocytes and membranes and ¹²⁵I-insulin binding and degradation studies, 801-809
isolated rat cells
insulin degradation by, 566-572
and insulin removal studies, *692
and insulin sensitivity, 225-229
ketogenesis and gluconeogenesis, *525
membrane glycoproteins
and obesity, *393
metabolism
in pyelonephritic rats, 887
mitochondrial metabolism
and insulin, *242-243
neonatal rat
and development of glucagon sensitivity, *410
and pancreatic islet allografts, *418
perfused guinea pig
gluconeogenesis from lactate and intracellular pH in, 618-623

phosphoenolpyruvate carboxylase and acid-base status in diabetic rat, *525-526
plasma membranes
in chronically diabetic rats, 257-261
insulin binding studies, *394
and insulin receptors, *395
steatosis
and endogenous hypertriglyceridemia, *1128
and tolazamide hepatotoxicity, *389
triglyceride and glycogen
and noradrenaline, *1033

LUNG
edema
and hypoglycemia, *426

LUTEINIZING HORMONE-
RELEASING HORMONE
pituitary responsiveness to
in insulin-dependent diabetics, 378-380

LYMPHOCYTES
cytotoxic
to cultured human insulinoma in insulin-dependent diabetics, *401
insulin binding to
and diabetes, *606
and obesity, *688
insulin receptors on
and insulin, *432
transformation by insulin and insulin fragments
and diabetes, 36-43

LYSINE
gastrointestinal absorption of, *309
in children, *243

M

MACACA NIGRA
diabetic
basement membrane thickness in muscle capillaries of, 201-206

MACROSEMIA
and insulin therapy
in pregnant diabetics, *439

MALNUTRITION
protein-calorie

and glucose tolerance and insulin secretion, *444

MALTOSE
metabolism
and intravenous maltose injection, *695

MANNOHEPTULOSE
and alloxan toxicity, 519

MANNOSE
and insulin secretion and biosynthesis, 197, 198

MAURIAC SYNDROME
and villous atrophy, *242, *308

MAXIMUM STIMULATION TEST
and insulin reserve in diabetic children, *432

MENTAL HEALTH
and factitial panniculitis, 858

METABOLISM
adipocyte
and hyperlipoproteinemia without obesity or diabetes, 207-212
adipocyte glucose
and exercise, *57
and adrenergic blockade, *1125-1126
amino acid
in diabetic ketoacidosis, 463-467
amino acid and nitrogen
and glucagon, *54
and behavioral disorders, *1128
brain
and alloxan diabetes, anti-insulin serum diabetes, and non-diabetic dehydration in mice, *781
carbohydrate, *see* Carbohydrate Metabolism
cholesterol
in alloxan diabetic rats, *57
in diabetes and obesity
with naturally labeled ¹³C-glucose, 185-189
and fasting, *242
fatty acid
modulation by glucagon, 1020-1025
free fatty acid
and glucagon, 502-508, 510-515
glucagon
in pregnant monkeys, *241, *307
glucose

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

compared with maltose metabolism, *695
 enzymes of, in adipose tissue of normal and diabetic subjects, 865-871
 and ethanol hypoglycemia, *693
 in pyelonephritic rats, 886
 in rat pancreatic islets, 476-487
 and streptozotocin in obese hyperglycemic mice, *688
 in thyroidectomized dogs, *1035
 and traumatic brain injury, *691
 in uremia, *1125
 glucose and palmitate and hindlimb perfusions of normal and diabetic rats, *448
 glutamine and glucagon, *1125
 glycogen in human fetal liver, 1101-1111, 1113-1122
 in muscle, *1129
 in identical diabetic twins, *385
 insulin and hypothyroidism, 922-925
 ketones and diabetes, *406
 and kidney glucagon and insulin uptake, *387
 leucine and redox potential, *415
 liver in pyelonephritic rats, 887
 maltose, *695
 mitochondrial and insulin, *242-243
 muscle, *387-388
 in non-diabetic offspring of diabetic parents, *433
 and oral contraceptives, *526
 phosphoinositide and insulin secretion, *399
 protein in heart muscle, insulin and, *780
 and regional adipose tissue cellularity in young and middle-aged women, *1127
 and serum tolbutamide half-life, *388
 splanchnic glucose and gluconeogenic substrate and glucose ingestion, 468-474
 and starvation, *308
 and *Streptococcus faecalis*-induced pyelonephritis, in rats, 881-889
 and tolbutamide, glucose and insulin interrelationships, 354-360
 and total parenteral nutrition, *406

METALS

chromium and diabetes, *406
 cobalt and insulin secretion and calcium uptake by isolated rat islets, *1127

METHEMALBUMIN

and diagnosis of acute hemorrhagic pancreatitis, *55

3-O-METHYL-D-GLUCOPYRANOSE

anomeric specificity against alloxan diabetes, *1035

3-O-METHYL GLUCOSE

and alloxan toxicity, 518-522

METHYLENE BLUE

and phenformin-associated lactic acidosis, 33

METHYLPREDNISOLONE

and exercise and glucose turnover in diabetic dogs, 915-920

METHYLBXANTHINES

and alloxan inhibition of insulin secretion, *400
 and glucose kinetics, 249-255

MICE

and alloxan diabetes, anti-insulin serum diabetes, and non-diabetic dehydration and brain carbohydrate and energy metabolism, *781
 diabetic and plasma glucose and lipid levels, and glucose tolerance factor, *446
 diabetic adrenalectomized and satiety center sensitivity to gold thioglucose damage, *385
 and obese-hyperglycemic syndrome and growth hormone deficiency, *1127
 growth pattern and behavioral traits associated with, *386-387
 and insulin receptor defects, *393
 and insulin receptors in heart muscle, 715-722
 and streptozotocin, *688
 spiny and carbohydrate-induced hypertriglyceridemia, *416

insulin secretion studies, 1094-1100

MICROANGIOPATHY, DIABETIC

and basement membrane abnormalities, 949
 and diabetes control, 8
 history of, 944-947
 and plasma fibrinogen, *438

MICROCIRCULATION

and diabetes, 944-952

MICROSCOPY

electron of diabetic dog pancreas, 340-343
 and diabetic microangiopathy research, 944-945
 and kidney collagen content, 1057-1064
 immunofluorescent and glomerular lesions in diabetic rats treated with pancreatic islet transplantation, 282-283

MICROTUBULAR-MICROFILAMENTOUS SYSTEM

and insulin release, 892-900

MINERALS

calcium binding to adipocyte plasma membranes, insulin and, *395
 and glucose transport, *448
 influx in beta cells, verapamil and, *400
 and insulin release, 1123, *1127
 chromium and glucose utilization, 350-352
 potassium homeostasis in human forearm tissues, *443

MIRSKY, I. ARTHUR, 776-778

MITOCHONDRIA

metabolism and insulin, *242-243, *309

MITOGEN

-induced lymphocyte transformation and diabetes, 36-43

MONKEYS

islet-stimulating factor in hypothalamus of, *436
Macaca nigra basement membrane thickness in

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

- muscle capillaries, 201-206
- and pregnancy
- and glucagon metabolism, *241, *307
- MONOAMINE OXIDASE**
- inhibition by adrenergic antagonists, phenformin and ethanol, *432
- inhibitors
- and insulin release, *1032
- liver and islet, *1126
- pancreatic islet, *1126
- MONTE CARLO MONITORING PROCEDURE**, 74-75
- MORTALITY**
- and diabetes
- and cardiomyopathy, *691
- in diabetes survey, *440
- and hemodialysis in chronic renal failure
- and diabetes, *1128
- of infants of diabetic mothers, *439
- and islet cell tumor surgery, *693
- and juvenile diabetes, 559-561, 563
- and malignant insulinoma
- and ectopic ACTH syndrome, 601
- and myocardial infarction in diabetics, *309-310, *1036
- and pancreatic abscess, *605
- in UGDP phenformin study
- and baseline characteristics of individual patients, 133-136
- and blood glucose control, 91-92
- by cause of death, 71-73
- effect of baseline differences on, 78-84
- and high adherence to treatment, 88
- and life tables, 155-160
- after protocol changes, 114-117
- statistical evaluation of, 73-78
- and statistical procedures, 162-168
- MULTIPLE LOGISTIC REGRESSION PROCEDURES**
- in UGDP study, 166-167
- MUSCLE**
- capillaries
- of South African diabetics, 286-290
- of diabetic rats
- and leucine metabolism, *415
- disused rat skeletal
- substrate utilization by, *387
- femoral capillary basement membrane
- in diabetic *Macaca Nigra*, 201-206
- glycogen metabolism, *1129
- heart
- insulin receptors in, 715-722
- and protein turnover and insulin, *780
- skeletal
- glutamine synthetase, diabetes and, *416
- glycogen synthase system, myotonic dystrophy and, *242
- and isoproterenol and protein turnover, *416
- and lipoprotein lipase, *417
- triglyceride and glycogen
- and noradrenaline, *1033
- MYELIN**
- sciatic nerve content of
- and aging and diabetes, *397, 680-683
- MYOCARDIAL INFARCTION**
- and cholesterol-altering drugs, *385
- and diabetes, *1036
- and coronary care units, *309-310
- and marathon running, *56
- and plasma catecholamines and carbohydrate metabolism, *55
- and serum glucagon and insulin levels
- and blood glucose, *694
- MYOINOSITOL**
- and peripheral motor nerve conduction velocity
- in streptozotocin diabetes, *1126
- MYOTONIC DYSTROPHY**
- and skeletal muscle glycogen synthase system
- and glucose and insulin administration, *242
- N**
- NATRIURESIS**
- and fasting, *242, *308
- NEPHROPATHY, DIABETIC**
- and mortality, 1
- NEPHROTIC SYNDROME**
- and insulin and growth hormone secretion, *1033
- NERVOUS SYSTEM**
- and Bell's palsy
- and diabetes, 449-451
- central
- insulin-sensitive glucoregulator center in, *417
- and gluconeogenesis
- and 2-deoxyglucose, *417
- and insulin secretion, *403
- insulin-sensitive glucoregulator receptor in, 328-335
- peripheral motor nerve conduction velocity
- and insulin and myoinositol in streptozotocin diabetes, *1126
- sciatic nerve
- axoplasmic flow in diabetic rats, 1081-1084
- myelin content, aging and diabetes and, *397, 680-683
- and stimulation of isolated canine pancreas
- and glucagon secretion, *439
- sympathetic
- and hepatic glycogenolysis during glucopenia, *1129
- sympathectomy
- and effect of theophylline on glucose kinetics, 249-255
- vagus nerve
- and gastric inhibitory polypeptide response to glucose, *389
- and gastrin release, *693
- and gastrin response to insulin, *388
- and glucagon release, *525
- and insulin and glucagon secretion, *387
- NEUROFIBROSARCOMA**
- and hypoglycemia and hyperinsulinemia, *1128
- NEUROPATHY, DIABETIC**
- and hearing, *1126
- and long-term juvenile diabetes, 562-563
- and plasma renin activity, *414
- and postural hypotension
- and 9-alpha-fluorohydrocortisone, 381-384
- NICOTINE**
- induced ³H-norepinephrine release
- and catecholamines, *1034
- NICOTINIC ACID**
- and fat cell metabolism, *690
- and glucagon secretion, *604
- NITROPRUSSIDE TEST**, 32

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

NOREPINEPHRINE
and liver and muscle triglyceride and glycogen concentrations, *1033

5'-NUCLEOTIDASE
and chronic diabetes, 258, 259

NUTRITION. *See also* Diet; Malnutrition
and carbohydrate intake
and biphasic insulin response to intravenous glucose, 1072-1079
parenteral
and metabolic balance, *406

O

OBESITY
in children
and carbohydrate intolerance and hypertriglyceridemia, *439
and diabetes risk factors, *434
and diabetic glomerulosclerosis, 2-3, 4, 6
and ethanol-induced alterations of glucose tolerance, postglucose hypoglycemia, and insulin secretion, 933-942
and exercise
and growth hormone, glucagon, and cortisol secretion, 758-761
and weight reduction in obese women, *1034
in women, *1034
and glucagon secretion
and hyperlipoproteinemia, *604
and glucose tolerance, 367
and hormone therapy, *606
and hyperglycemia in mice
and insulin receptors in heart muscle, 715-722
and streptozotocin, *688
and insulin binding to receptors
and calorie restriction, *688
and insulin receptor defects, *393
and insulin secretion in prediabetics, *445
and insulin secretion from rat perfused islets, *436
massive
and portal and peripheral insulin measurement, *447
and metabolism, 185-189
and renal conservation of ketone bodies
during starvation, *606-607

and serum growth hormone levels in maturity-onset diabetics, 979-981
and weight reduction
and outpatient semistarvation, *690

ORAL CONTRACEPTIVES
and metabolism, *526

ORAL HYPOGLYCEMIC AGENTS
and hyperlipemia, *604
and myocardial infarction, *1036
and vascular complications in diabetics, *see* UGDP Phenformin Study

OUABAIN
and L-isoleucine stimulation of glycolysis, 482
and sodium-potassium adenosine-triphosphatase, *438

OXYGEN
transport
and diabetes, 952

P

PALMITATE
metabolism
and hindlimb perfusions of normal and diabetic rats, *448

PANCREAS
abscess, *605
alpha- and beta-cell interrelationships, *310
alpha- and beta-cell responses to glucose
and deoxyglucose infusion in neonatal sheep, *604-605
alpha cell
response to hypoglycemia, 298-299
alpha-cell dysfunction
and diabetes, *410
artificial, *689
and assessment of antidiabetic action of somatostatin, 988-996
artificial endocrine, *404
beta cell culture on synthetic capillaries, *689
beta-cell damage
and viruses, *779
beta-cell hyperplasia

and hypoglycemia, *243
beta-cell microtubular microfilamentous system
and insulin release, *694, 892-900
beta cells
and alloxan toxicity, 516-522
autoimmunity to, *401
calcium influx in, verapamil and, *400
glibenclamide binding to, *308
glucose receptor and beta-adrenergic receptor, 536
membrane potential, *387
vesicular binesis, *398
bovine
dual islet population in, *421
of diabetic dog, 340
disease
and endoscopic pancreatography, *689-690
exocrine
and somatostatin, *408
fetal islet beta cell
and decreased glucose excitation, *400
fetal and neonatal
intraperitoneal isotransplantation of, *419
glucagon
and glucose homeostasis, *780
interactions with gut glucagon, vasoactive intestinal polypeptide, and secretin, *54
glucagon and insulin
and burns, *694
human neonatal
transplantation of, *421
insulin content
and growth hormone, ACTH, cortisol, dexamethasone, and tolbutamide, *688
and insulin and glucagon secretion
and vagus nerve, *387
and insulin secretion
and cerebral intraventricular insulin in dog, 910-914
islet allografts
liver as immunologically privileged site for, *418
islet-cell antibodies
in insulin-dependent diabetics with autoimmune disease, *606
islet cell carcinoma
and ectopic ACTH syndrome, and hypoglycemia, 600-603
islet cell transplantation, *55
and glomerular lesions in diabetic

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

rats, 280-285
 islet cell tumors, *693
 islet function
 and calcium antagonists, 547-551
 islet isografts
 intrahepatic portal vein, *419
 spleen as site for, *437
 islet monoamine oxidase
 inhibition by adrenergic antagonists, phenformin and ethanol, *432
 islets
 actin content, *605
 alpha- and beta-cell secretory responses, 961-970
 and diazoxide in dogs, 1048
 digestion-filtration method for isolation of, *444
 glucose penetration and glucagon suppression in, *440
 immunoglobulins binding to, 230-236
 monoamine oxidase, *1126
 of neonatal rats, cyclic AMP and insulin response to glucose in, 746-751
 neogenesis, and cortisone, *447
 and proinsulin-insulin and protein biosynthesis after glucose exposure, 194-200
 and sodium-potassium adenosine-triphosphatase, *438
 islet-stimulating factor in monkeys, *436
 isolated dog
 and neural stimulation and glucagon secretion, *439
 isolated islets
 and alloxan and cyclic-3'5'-AMP levels and insulin release, *405
 and DNA synthesis, *1032
 and glucagon secretion and high protein diet, *409
 and insulin biosynthesis, 373-376
 isolated perfused rat
 and amino-acid-induced glucagon and insulin release, *526
 and insulin and glucagon secretion and alpha- and beta-D-glucose studies, 369-371
 isolated rat islets
 and glucose and amino acid interactions, 489-495
 and glucose metabolism studies, 476-487
 mechanical, 1123

neonatal
 and is transplantation studies, *435
 and occult adenocarcinoma
 and immunosuppressed leukemia, *243
 perfused, of diabetic Chinese hamster
 and arginine response, 272-278
 perfused rat
 and glucose-stimulated insulin release, *690
 and stimulation of glucagon secretion by scorpion toxin, *409
 pseudocysts
 spontaneous resolution of, *689
 rat
 cyclic AMP and amylase output and gastrointestinal hormones, *1033
 rat islets
 preparation of plasma membranes from, *399
 transplantation
 long-term exocrine function, *689
 into retroperitoneal jejunal loop, *604

PANCREATECTOMY

and big plasma glucagon in plasma, *411
 and glucose turnover and free fatty acid concentrations, *525
 and production of chylomicron-like lipoproteins from endogenous lipid, 263-270

PANCREATITIS

acute and chronic
 and diabetes, *388-389
 acute hemorrhagic
 methemalbumin in diagnosis of, *55
 chronic
 in African diabetics, *694
 and immunoreactive glucagon responses to intravenous tolbutamide, 851-855
 and pseudocysts, *689

PANCREATOGRAPHY

endoscopic
 and assessment of pancreatic disease, *689-690

PANNICULITIS

factitial, 856-858

PARATHYROID GLAND

disorders

and serum calcium effect on insulin release, *1037
 function
 and alloxan diabetes, *58
 in infants of diabetic mothers, *1036

PENTOSE PHOSPHATE SHUNT

and insulin secretion by isolated islets, *427

PEPSIN

secretion
 and glucagon, *780

C-PEPTIDE

assay
 and insulin suppression of insulin secretion, *403
 in portal and peripheral blood of normals, *1034

PEPTIDE HORMONES

transport across isolated rat mesentery, 997-1004

PERITONITIS

and differential tissue sensitivity to elevated endogenous insulin levels, *692

pH

liver cell
 and gluconeogenesis and phenformin, 618-623

PHAGOCYTOSIS

and diabetic control, *426

PHENETHYLBIGUANIDE

and lactic acidosis
 and insulin therapy, 28-33

PHENFORMIN. See also UGDP Phenformin Study

and gluconeogenesis from lactate and intracellular pH in liver, 618-623
 -induced lactic acidosis, *428, *430, *440
 and diabetes, 791-799
 and insulin therapy, 28-33
 and latent diabetes therapy, *443
 and lipid transport
 and hypertriglyceridemia, *58
 and pancreatic islet monoamine oxidase, *432

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

SUBJECT INDEX 1975

- and plasma glucagon suppression, *428
- therapy
 - and lactic acidosis, 741-744
 - and serum vitamin B-12 levels, *439
 - and vascular disease, *397
- PHENTOLAMINE**
 - and shock-induced hyperglucagonemia, 314
 - and ventromedial hypothalamic nucleus stimulation, *386
- PHENYLBUTAZONE**
 - and glibenclamide binding to pancreatic beta cells, *308
- PHENYLEPHRINE**
 - and postgastrectomy hypoglycemia, 1005-1009
- PHLORIDZIN**
 - and L-isoleucine stimulation of glycolysis, 482-483
- PHOSPHOENOLPYRUVATE CARBOXYKINASE FERROACTIVATOR**, *416
- PHOSPHOENOLPYRUVATE CARBOXYLASE**
 - in diabetic rat
 - and acid-base status, *525-526
- PHOSPHOINOSITIDE**
 - metabolism
 - and insulin secretion, *399
- PHOSPHORYLASE**
 - in heart
 - and insulin and epinephrine, *1128-1129
 - in human fetus, 1104-1105
- PHOSPHORYLASE PHOSPHATASE**
 - in human fetus, 1103, 1104-1105
- PHYTOHEMAGGLUTININ**
 - and cell-mediated immunity in diabetes, 39-43
- PIMA INDIANS**
 - and diabetes diagnosis
 - and glucose tolerance tests, 538-545, 546
 - and diabetes risk factors study, *434
 - and glucagon response to arginine, *427
- and insulin release to intravenous glucose in prediabetics and normals, *402
- and insulin responses to oral carbohydrate, *1036
- PITUITARY GLAND**
 - irradiation
 - and pituitary hormone function in diabetics, *395
 - and luteinizing hormone-releasing hormone and insulin-dependent diabetics, 378-380
- PLACEBO THERAPY**
 - in UGDP phenformin study, 67-68, 133, 137-139
 - and life tables, 155-160
 - variability among clinics, 168
- PLACENTA**
 - barrier to insulin I²⁵
 - in insulin-dependent diabetics, *605
- PLASMA**
 - alanine
 - and glucagon, *1125
 - and ketones, *406
 - aldosterone
 - in uncontrolled diabetes, 191-193
 - amino acid levels
 - and diabetic ketoacidosis, 466-467
 - B-OH butyric acid
 - in starvation ketosis study, 11-16
 - catecholamines
 - and acute myocardial infarction, *55
 - cell dyscrasia
 - polyneuropathy and endocrine disturbances, *56
 - cortisol
 - and traumatic brain injury, *691
 - cortisol and growth hormone
 - and starvation, *242
 - epinephrine and norepinephrine
 - and acute myocardial infarction, *55
 - fibrinogen
 - and diabetic microangiopathy, *438
 - free fatty acids
 - and glucagon secretion, *604
 - and growth hormone release, 848
 - and starvation, 10-16
 - glucagon
 - in depancreatized, alloxanized and phloridzinized dogs, *412
 - in nonketotic hyperosmolar coma, *56
 - phenformin suppression of, *428
 - in pregnant monkeys, *241
 - and rapid exsanguination and adrenergic blockade, 313-315
 - glucagon and insulin
 - and oral alanine feeding in small-for-gestational-age infants, *1036
 - in pregnant rats, *607
 - glucagon and insulin and free fatty acids
 - and fasting, *692
 - glucose
 - in alloxan toxicity studies, 517-518
 - and diabetes diagnosis, 642-644
 - and endogenous hyperlipoproteinemia without diabetes or obesity, 209
 - and ethanol in fasted man, 295-299
 - and fasting, *692
 - and insulin dosage in diabetic ketoacidosis, *396
 - response to glucagon and tolbutamide, somatostatin and, *690
 - and starvation ketosis, 10-16
 - in Toubou Broayas, 983-986
 - glucose, free fatty acid, insulin, glucagon, and cortisol
 - and trauma, *691-692
 - glucose and glucagon
 - and somatostatin, *242, *308
 - glucose and insulin
 - and intracisternal insulin in dog, 905-909
 - glucose, insulin, glucagon and triglycerides
 - and diet, 552-557
 - glucose and lipid levels
 - reduction by glucose tolerance factor, *446
 - growth hormone
 - and diabetes, 317-326
 - and somatostatin, *526
 - growth hormone, insulin and glucagon
 - and somatostatin, 842-849
 - 3-hydroxybutyrate and lactate
 - and alcoholic ketosis, 785-786, 787
 - immunoreactive insulin and glucagon
 - after evisceration with and without functional liver, 637-640
 - insulin
 - in children with long-standing diabetes, *447
 - and endogenous hypertriglyceridemia, *1128
 - during intravenous glucose tolerance tests, 21
 - and neurofibrosarcoma, *1128

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

- response to glucagon and tolbutamide, somatostatin and, *690
- insulin and glucagon
 - in normal and diabetic Chinese hamsters, *448
 - in diabetes therapy study, 815-816
- insulin and glucose responses to ventromedial hypothalamic stimulation, *386
- insulin removal rate
 - and intravenous glucose infusion, *57
- ketone bodies
 - and glucagon, 1021-1022
 - response to medium-chain triglycerides in experimental hyperosmolar diabetic syndrome, 301-305
- lipids
 - and hyperinsulinemia and enlarged adipocytes in patients without diabetes or obesity, 207-212
 - in juvenile diabetics, 672-678
- lipoprotein lipase
 - and glucagon, *241, *307
- membrane
 - insulin binding in, 715-722
- of pancreatectomized patient
 - and big plasma glucagon in, *411
- C-peptide
 - and diagnosis of factitious hyperinsulinism, *1033
- phenformin,
 - and lactic acidosis, 791-799
- platelet aggregation
 - and diabetes, *398
- renin activity, *425
 - and diabetes and neuropathy, *414
 - and diabetes with renal failure, *441
 - and juvenile diabetes, diazoxide and, 833-835
 - and oral blood glucose lowering agents, *429
 - in uncontrolled diabetes, 190-193
- triglyceride labeling
 - and high-sucrose diet, *694-695
- triglycerides
 - and basal and postprotein insulin and glucagon levels, 552-557
- ultrafiltrates
 - and inhibition of glyceraldehyde-3-phosphate dehydrogenase, *1129
- PLASMINOGEN
 - activator activity of vein walls
- and diabetic retinopathy, 530, 531
- PLATELETS
 - aggregation
 - and diabetes, *428, *1035
- POLYNEUROPATHY
 - plasma cell dyscrasia and endocrine disturbances and, *56
- POLYPEPTIDES
 - gastric inhibitory
 - and glucose tolerance in normal and diabetic man, *413
 - response to glucose, *389
 - and serum immunoreactive insulin response to glucose in dogs, 1050-1056
 - intestinal
 - and cyclic AMP and amylase output in rat pancreas, *1033
- PORPHYRIA CUTANEA TARDA
 - and diabetes, *433
- PORTAL VEIN
 - glucose and glucagon
 - and prostaglandin E, *430
 - isologous islets injected into, *419
 - serum insulin concentration
 - in normal male rats, 226
- POTASSIUM
 - homeostasis
 - in human forearm tissues, *443
 - and insulin and glucagon secretion, *310
- PREDIABETES
 - and glucagon response to arginine
 - in Pima Indians and Caucasians, *427
 - and insulin, growth hormone and glucagon responses, *386
 - and insulin release to intravenous glucose, *402
 - and insulin responses to oral carbohydrate, *1036
 - and insulin secretion
 - and obesity, *445
- PREDNISONE
 - and diabetic pregnancy, 498
- PREGNANCY
 - in fasted rats
 - and ketosis and lipemia, *445
 - nonhuman primate
 - and glucagon metabolism, *241
 - in rats
 - and plasma glucagon and insulin, *607
- PREGNANCY, DIABETIC
 - diagnosis of
 - and three-hour oral glucose tolerance tests, 874-880
 - and "fast" hemoglobin, *415
 - and insulin requirements after cesarean section, *605
 - and insulin therapy
 - and macrosema, *439
 - and neonatal hypoglycemia, *411
 - and placental barrier to insulin I²⁵, *605
 - after renal transplantation, 497-501
- PROBANTHELINE
 - treatment
 - and idiopathic reactive hypoglycemia, *425
- PROINSULIN
 - biosynthesis, 194-200
 - and insulin biosynthesis, *693
 - like component
 - from normal and diabetic serum, 615-616
 - and lipolysis in isolated fat cells, 238-239
 - messenger RNA
 - purification and translation of, *405
 - translation of, *405
 - in portal and peripheral blood of normals, *1034
 - specific IgG antibodies
 - and monocomponent insulin, 625-632
- PROINSULINEMIA
 - familial, *413
- PROLACTIN
 - binding studies, *309
- PROPIONATE
 - induced growth hormone release
 - and somatostatin, 844-845
- PROPRANOLOL
 - glucagon stimulation
 - and growth hormone and cortisol secretion, *58
 - and hypoglycemia
 - and insulinoma, 535-537
 - and intravenous glucose infusion

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

- and plasma insulin removal rate, *57
 - long-term therapy
 - and insulin response to intravenous glucose, *55
 - and postgastrectomy hypoglycemia, 1005-1009
 - and shock-induced hyperglucagonemia, 314-315
 - and sulfonylurea-stimulated insulin secretion in dogs, *444
- PROSTAGLANDIN E₁**
- and fat cells, *690
 - and growth hormone release and somatostatin, 847-848
 - and inhibition of insulin secretion, *58
 - and portal vein glucose and glucagon and hepatic glycogen synthase, phosphorylase and glycogen, *430
- PROTEASE**
- insulin-glucagon
 - and glucagon degradation, *426
- PROTEIN(S)**
- action
 - in pancreatic islet cells, *605
 - biosynthesis, *693
 - by pancreatic islets after glucose exposure, 194-200
 - calorie malnutrition and glucose tolerance and insulin secretion, *444
 - dietary
 - and glucagon secretion, *409
 - and insulin and glucagon levels, 552-557
 - islet-binding immunoglobulins, 230-236
 - phosphoenolpyruvate carboxykinase
 - ferroactivator
 - and diabetes and fasting, *416
 - renal clearance and diabetic retinopathy, *436
 - turnover
 - and chronic diabetes, 257-261
 - and isoproterenol, *416
 - turnover in heart muscle and insulin, *750
- PROTEINURIA**
- and diabetic retinopathy, 532
- PSAMMOMYS OBESUS**
- and stress
- and triglyceride secretion, *441
- PSEUDOCYSTS**
- pancreatic, 851
 - spontaneous resolution of, *689
- PULMONARY SYSTEM**
- embolism and urokinase and streptokinase, *307
- PYELONEPHRITIS**
- Streptococcus faecalis-induced in rats and metabolism studies, 881-889
- PYRAZOLE**
- and starvation ketosis studies, 10-16
- PYRUVATE**
- and leucine metabolism by muscles of diabetic rats, *415
- PYRUVATE DEHYDROGENASE**
- and exercise, starvation, and diabetes, *415

R

- RABBITS**
- and cortisone and islet cell neogenesis, *447
 - and hypoglycemic seizures and coma, *307
 - and sciatic nerve myelin content and aging and diabetes, *397, 680-683
- RACE**
- and glucagon response to arginine and prediabetes and diabetes, *427
 - and insulin release to intravenous glucose, *402
 - and muscle capillary thickening and retinopathy, 286, 287
 - of UGDP patients, 70, 71, 121 and mortality, 79-83
- RADIOIMMUNOELECTROPHORESIS**
- of monocomponent insulin, 627
- RATS**
- alloxan diabetic and adrenocortical system, *242
 - and cholesterol metabolism, *57
- and isotransplantation of organ cultured neonatal pancreases, *435
 - and parathyroid function, *58
 - reversal of, *420
 - and antiketogenic action of fructose, glyceraldehyde, and sorbitol, 926-931
 - and artificial endocrine pancreas, *689
 - central nervous system insulin-sensitive glucoregulator receptor, 328-335
 - chlorpromazine-induced growth hormone release and hypothalamic surgery and somatostatin, *691
 - diabetic
 - and acid-base status effect on phosphoenolpyruvate carboxylase, *525-526
 - and amino-acid induced glucagon release, *692
 - and axoplasmic flow in sciatic nerve, 1081-1084
 - and insulin binding by liver plasma membranes, *394
 - and pancreatic islet transplantation, effect on glomerular lesions, 280-285
 - disused skeletal muscles and substrate utilization, *387-388
 - erythrocytes and streptozotocin, *399
 - and ethanol and isoproterenol-induced hyperglycemia, *57
 - eviscerated
 - with functioning liver and acute diabetes, *418
 - and exercise
 - and adipocyte glucose metabolism and insulin responsiveness, *57
 - and experimental hyperosmolar diabetic syndrome and ketogenic response to medium-chain triglycerides, 301-305
 - and experimental peritonitis and differential tissue sensitivity to insulin levels, *692
 - and experimental shock and insulin resistance, *55
 - fetal and newborn and insulin biosynthesis studies, 373-376
 - with and without functional liver

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

and plasma immunoreactive insulin
and glucagon, 637-640
and glibenclamide
and insulinogenic duodenal factors,
*413
and glucagon activity
and hyperlipemia, *604
and glucose-mediated insulin response
and ethanol, *440
and high-protein diet
and glucagon secretion, *409
and insulin resistance
and glycolytic enzymes, *388
and islet transplants, *420
spleen as site for, *437
isolated perfused liver
and insulin sensitivity studies,
225-229
liver cells
insulin degradation by, 566-572
liver glucose-6-phosphatase activity
and glycogen content
and thyroid state, *688
neonatal
cyclic AMP and insulin response to
glucose in isolated islets of,
746-751
neonatal liver
and glucagon sensitivity, *410
normal and sympathectomized
and theophylline and glucose kine-
tics, 249-255
pancreas islets
glucose penetration and glucagon
suppression in, *440
and pancreatic islet allografts
and liver as site for, *418
and pancreaticoduodenal isografts
and long-term exocrine function,
*689
and peritonitis
and differential tissue sensitivity to
elevated endogenous insulin
levels, *692
pregnant
and plasma glucagon and insulin,
*607
pregnant fasted
and ketosis and lipemia and diet,
*445
pyelonephritic
and metabolism studies, 881-889
and retinal sorbitol metabolism, *386
serum insulin, growth hormone and
thyroxine
inter-strain differences in, *308
skeletal muscle

and lipoprotein lipase, *417
streptozotocin diabetic
and cell membrane studies, 257-261
and glucose and palmitate
metabolism, *448
and leucine metabolism, *415
and motor nerve conduction veloc-
ity studies, *1126
and sodium retention studies,
645-648
and somatomedin deficiency, *407
and treatment with growth hormone,
ACTH, cortisol, dex-
amethasone and tolbutamide
and pancreatic and serum insulin
and blood glucose, *688
and tris inhibition of sucrose, *692
and ventromedial hypothalamic stimu-
lation
and plasma insulin and glucose,
*386

RBO ANALYSIS, 162-165

REDOX POTENTIAL
and leucine oxidation by muscles of
diabetic rats, *415

RELATIVE BETTING ODDS. *See*
RBO Analysis

RENIN-ANGIOTENSIN SYSTEM
and oral contraceptives, *526

RETINA
diabetic
and microangiopathy, 945
sorbitol metabolism
and streptozotocin-induced dia-
betes, *386

RETINOPATHY, DIABETIC
and diabetic glomerulosclerosis, 7
exudative stage
and hypertensive arteriosclerosis,
*435
and fibrinolytic system, 529-533
and growth hormone deficiency, 1030
and insulin injections, *397
and long-term juvenile diabetes,
561-562
and muscle capillaries of diabetics,
286-290
and renal protein clearance, *436

RNA
¹⁴C-adenine incorporation into

and glycolytic enzymes, *388
fish islet messenger
isolation by oligo-dT cellulose affi-
nity chromatography, *405
pancreatic messenger
cell-free translation of, *405
proinsulin
purification and translation of, *405

ROCHESTER, MINNESOTA
diabetes survey in, *440

S

SALINE
infusion
and fatty acid metabolism, 503-504,
511

SANDERSON, EDWARD W., 390

SANDFLY FEVER
and glucose utilization
and serum chromium, 350-352

SCIATIC NERVE
axoplasmic flow in diabetic rats,
1081-1084
myelin
and aging and diabetes, *397,
680-683

SCORPION TOXIN
and glucagon secretion in perfused rat
pancreas, *409

SECRETIN
and insulin responses to glucose and
arginine, *438
interactions with pancreatic and gut
glucagon, vasoactive intesti-
nal polypeptide, liver, and
fat, *54
release
and somatostatin, *408

SERUM
albumin
and glibenclamide binding to pan-
creatic beta cells, *308
anti-insulin
and insulin released from isolated is-
lets of Langerhans in long-
term organ culture, 658-662
calcium
and insulin release, *1037

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

calcium and parathyroid hormone
and glucose metabolism in uremia,
*1125

cholesterol
and cholesterol-altering drugs in
coronary heart disease pa-
tients, *385
and diet, *425
of UGDP phenformin study pa-
tients, 105-106, 127, 175

chromium
and glucose utilization, 350-352

creatinine
and lactic acidosis, 743
in UGDP study, 103-104, 127, 174

globulin binding to islet tissue, 230-236

glucagon and insulin levels
and blood glucose values in acute
myocardial infarction and
acute coronary insufficiency,
*694

glucose
and diabetes with Bell's palsy study,
450
and hyperosmolar nonketotic coma,
595

glucose, insulin, and glucagon
and burns, *694

growth hormone, twenty-four-hour
levels in maturity-onset
diabetics, 977-981

immunoassayable insulin levels
and chemical diabetes, 753

immunoreactive insulina
and monoclonal immuno-
globulinemia, 214-223
response to glucose, gastric inhibi-
tory polypeptide and,
1050-1056

immunoreactive parathyroid hormone
and alloxan diabetes, *58

inorganic sulfate
and somatomedin activity, *385

insulin
and glucose infusion in premature
infants, 291-293
and growth hormone, ACTH, cor-
tisol, dexamethasone, and tol-
butamide, *688

insulin, growth hormone and thyrox-
ine
in different rat strains, *308

lipids
in maturity-onset diabetics, *434

osmolality and osmolality
and hyperosmolar nonketotic dia-
betic coma, 595-597

polypeptide hormones
immunoassay, *779

proinsulin
and chemical diabetes, 753-756

tolbutamide
half-life, *388

triiodothyronine
and dietary composition, weight
gain and thermogenesis, *406

ultrafiltrates
and inhibition of
glyceraldehyde-3-phosphate
dehydrogenase, *1129

viscosity
and diabetes, 1124

vitamin-B-12 levels
and phenformin-treated diabetics,
*439

SEX

and cell-mediated immunity in dia-
betes, 37, 38

and diabetes with Bell's palsy, 450,
451

and diabetic glomerulosclerosis, 2

and female diabetics, *432

and glucose tolerance tests in Pima
Indians, 540-542

and glucose tolerance in Toubou
Broayas, 983-986

and immunoreactive glucagon re-
sponses to intravenous tol-
butamide
and chronic pancreatitis, 853

and mortality in UGDP phenformin
study, 79-83

and muscle capillary thickening
and retinopathy, 286, 287

and myocardial infarction mortality in
diabetics, *1036

and pancreatic response to arginine by
Chinese hamsters, 274-275

of patients in UGDP study, 70, 71

and plasma glucose during fasting,
*692

and plasma lipid levels of juvenile
diabetics, 676

and renal papillary necrosis, *54

of UGDP patients, 120, 121

SHEEP

neonatal
insulin-glucagon substrate inter-
relationships in, *604-605

and somatostatin
and plasma growth hormone, insu-
lin, and glucagon, 842-849

SHOCK

induced in rats
and insulin resistance, *55
and plasma glucagon
and adrenergic blockade, 313-315

SKIN

and diabetic changes, 947

infection
and insulin injections, 856-858

SODIUM

depletion
and plasma renin activity, *414

retention
and insulin treatment in
streptozotocin-diabetic rats,
645-648

SODIUM BICARBONATE

and alcoholic ketosis, 788

-insulin-saline therapy
and amino acid levels in diabetic
ketoacidosis, 463-467

and phenformin-induced lactic
acidosis, 796

regulation by cerebrospinal fluid
and respiratory acidosis and al-
kalosis, *781

SODIUM-POTASSIUM

ADENOSINETRIPHOS- PHATASE

in pancreatic islets
and ouabain, diphenylhydantoin,
and calcium, *438

SOMATOMEDIN

activity, *385
and growth failure in juvenile diabet-
ics, *407

SOMATOSTATIN

antidiabetic action of
assessment by artificial pancreas,
988-996

and blood glucose, plasma growth
hormone, insulin, and free
fatty acids and acromegaly,
*526

and chlorpromazine-induced growth
hormone release in rats, *691

and glucagon and insulin release, 1124

and liver glucose output in normal
dogs, *407

and glucagon suppression
and hyperglycemia, *1033

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- and glucose homeostasis
and pancreatic glucagon, *780
and growth hormone and insulin secretion
and acromegaly, *1033-1034
immunoassays, 1124
-induced decreases in immunoreactive insulin and glucagon
and glucose turnover, *408
and inhibition of insulin and glucagon secretion
reversal of, *408
and insulin release and glucagon release
in islets isolated with collagenase
and isolated perfused pancreas, 961-970
and plasma glucose and glucagon levels in diabetics, *242, *308
and plasma glucose and insulin responses to glucagon and tolbutamide, *690
and plasma growth hormone, insulin and glucagon in sheep, 842-849
and secretin release and pancreatic exocrine function, *408
- SORBITOL**
antiketogenic action of, 926-931
metabolism
in retina, *386
- SPLANCHNIC NERVE**
glucose and gluconeogenic substrate metabolism
and oral glucose ingestion, 468-474
glucose production
and gluconeogenesis study, 577
ketone body release, *525
- SPLEEN**
and islet isografts
in diabetic rats, *437
- STARVATION. See also Fasting**
and amino acid and nitrogen metabolism
and glucagon, *54
glucagon responses to
and adrenergic blockade, *526
and hypoglycemia
and beta-cell hyperplasia, *243
and metabolism, *242, *308
and plasma glucose stabilization, *692
and plasma lipoprotein lipase and glucagon, *307
- and pyruvate dehydrogenase, *415
and renal conservation of ketone bodies, *606-607
and ventromedial hypothalamic nucleus stimulation, *386
- STOMACH**
alpha-cell function
in normal and diabetic dogs, *411
- STREPTOCOCCUS FAECALIS**
-induced pyelonephritis in rats
and metabolism studies, 881-889
- STREPTO**
and carcinoid syndrome
and insulin secretion and glucose tolerance, 670
- STREPTOKINASE**
and pulmonary emboli, *307
- STREPTOZOTOCIN**
and erythrocyte glutathione levels and glutathione reductase activity, *399
and glucose metabolism, insulin response and adiposity in obese hyperglycemic mice, *688
and islet cell carcinoma, 600
- STREPTOZOTOCIN DIABETES**
and cell membrane changes, 257-261
and glomerular basement membrane synthesis, *429
and glomerular lesions in rats treated with pancreatic islet transplantation, 280-285
and glucose penetration and glucagon suppression in pancreas islets, *440
and insulin and glucose and modulators of amino-acid induced glucagon release, *692
and insulin therapy
and sodium retention, 645-648
and islet transplantation
spleen as site of, *437
and leucine metabolism by muscles, *415
and pancreatic islet allografts
liver as site for, *418
and peripheral motor nerve conduction velocity
and insulin and myoinositol, *1126
in rats
and fast and slow axoplasmic flow in sciatic nerve, 1081-1084
and retinal sorbitol metabolism in rat, *386
and skeletal muscle glutamine synthetase, *416
and somatomedin deficiency, *407
- STRESS**
and triglyceride secretion, *441
- SUCRASE**
and tris, *692
- SUCROSE**
feeding
and plasma triglyceride labeling, *694-695
inhibition by tris in rat and man, *692
- SULFHYDRYL-BINDING REAGENTS**
and insulin release from isolated secretion granules, *310
- SULFONYLUREAS**
and catecholamine release, *1034
and glibenclamide binding to pancreatic beta cells, *308
glibenclamide and chlorpropamide in maturity-onset diabetics, *689
and hepatotoxicity, *389
-induced insulin release
and verapamil, 549
-stimulated insulin secretion
and propranolol and ergot alkaloids, *444
therapy
and glucagon response to arginine, 814-815
- SURGERY. See also Transplantation**
femoropopliteal and femorotibial bypasses, *397
femorotibial bypass
and ischemia of lower extremity in diabetics, *1129
gastrectomy
and hypoglycemia and adrenergic agents, 1005-1009
hypothalamic
and chlorpromazine-induced growth hormone release in rats, *691
and islet cell tumors, *693
and pancreatic pseudocysts, *689
sympathectomy
and effect of theophylline on glucose

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

kinetics, 249-255
vagotomy
and gastrin response to insulin, *388
vagotomy and pyloroplasty
and gastric inhibitory polypeptide
response to glucose, *389

SYMPATHETIC NERVOUS SYSTEM
and hepatic glycogenolysis, *1125

SYMPATHO-ADRENAL SYSTEM
and tolbutamide, *414

T

TASTE PERCEPTION
and diabetes, *414

TEMPERATURE
cold exposure
and glucose metabolism in
thyroidectomized dogs, *1035

TENDONS
collagen
and aging and diabetes, 902-904

THALASSEMIA MAJOR
and pancreatic islet cell function
and carbohydrate metabolism, *430

THEOPHYLLINE
and cyclic AMP and amylase output in
rat pancreas, *1033
and glucose kinetics
in normal and sympathectomized
rats, 249-255
and glyceraldehyde isomers
and insulin release, *403
and pancreatic response in diabetic
Chinese hamsters, 272-278

³H-THYMIDINE
uptake by lymphocytes
and diabetes, 39

THYROID GLAND
autoimmune thyroiditis
and carbohydrate tolerance,
829-832
diseases
and insulin metabolism, 922-925
hormones
and obesity therapy, *606
and rat liver glucose-6-phosphatase
activity and glycogen content,
*688

THYROIDECTOMY
and glucose metabolism in dogs
and rest and cold exposure, *1035

L-THYROXINE
and rat liver glucose-6-phosphatase ac-
tivity and glycogen content,
*688

TISSUES
adult rat isolated islets of Langerhans
effect of glucose and anti-insulin
serum on insulin released
from, 658-662
beta cells of isolated rat islets
binesis studies, *398
differential sensitivity to endogenous
insulin levels
and experimental peritonitis in rats,
*692

fetal islet
and transplantation, 770-771
hepatocytes from fed rats
and gluconeogenesis studies, *429
human adipocyte in vitro
and insulin sensitivity studies,
1086-1092
human adipose
and fatty acid synthesis, *780
human fetal liver explants
and hormonal regulation of
alanine-U-¹⁴C incorporation
into glucose in, 650-656
human forearm
and potassium homeostasis studies,
*443

insulin, growth hormone and prolactin
binding
and species variation, *309
isolated fat cells
and adenosine deaminase, *690
and lipolysis studies, 238-239
isolated hepatocytes
and glycogen synthase and
glycogenesis study, *425
isolated islets of neonatal rats
cyclic AMP and insulin response to
glucose in, 746-751
isolated pancreas of diabetic rats
and glucagon release studies, *692
isolated perfused rat heart
and glucagon, *689
isolated perfused rat islets
and glucose and amino acid interac-
tion study, 489-495
isolated perfused rat liver
and insulin sensitivity studies,
225-229

isolated perfused rat pancreas
and insulin and glucagon secretion
and alpha- and beta-D-
glucose studies, 369-371
and verapamil inhibition of insulin
release, 547-551
isolated perfused rat islets
and cyproheptadine and insulin se-
cretion studies, 836-841
isolated rat heart cells
and hormone action studies, *429
isolated rat hepatocytes and adipo-
cytes
insulin binding studies on, *1129
isolated rat islets
and cobalt inhibition of insulin
secretion and calcium uptake,
*1127
and glucose metabolism studies,
476-487
and insulin secretion and pentose
phosphate shunt, *427
and lectins and hormone release,
705-713
isolated rat liver cells
insulin degradation by, 566-572
isolated rat mesentery
transport of peptide hormones
across, 997-1004
isolated rat pancreatic islets
and insulin biosynthesis studies,
373-376
liver plasma membranes
and chronic diabetes, 257-261
liver slices
and mitochondrial metabolism
studies, *242-243
mouse diaphragms
and glycogen metabolism studies,
*1129
pancreatic
and digestion-filtration method,
*444
perfused guinea pig liver
gluconeogenesis from lactate and in-
tracellular pH in, 618-623
perfused rat liver
and insulin removal rates, *692
perfused rat pancreas
and glucose-stimulated insulin re-
lease, *690
perfused pancreas islets
and insulin secretion studies, *436
plasma membranes from rat islets
preparation of, *399
rat adipose
and effect of insulin and cortisol on
insulin receptors, *394

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

SUBJECT INDEX 1975

- rat liver plasma membranes and isolated hepatocytes
and ¹²⁵I-insulin binding studies, 801-809
- splanchnic and peripheral and glucose disposal, 468-474
- toadfish islet
and insulin release and sulfhydryl-binding reagents, *310
- TOLAZAMIDE**
and catecholamine release, *1034
hepatotoxicity, *389
- TOLBUTAMIDE**
and cardiac effect, *525
and catecholamine release, *1034
and chemical diabetes in children, *434
and glucagon secretion, *410
and glucose and insulin
and intravenous tolbutamide, 354-360
immunoreactive glucagon responses to
in chronic pancreatitis, 851-855
and pancreatic and serum insulin and blood glucose, *688
plasma glucose and insulin responses to
and somatostatin, *690
and prevention of cardiovascular disease, *414
response
in nondiabetic offspring of diabetic parents, *433
serum half-life, *388
and sympatho-adrenal system, *414
- TOLBUTAMIDE TEST**
intravenous, 354-360
in pyelonephritic rats, 884
- TRANSFERRIN**
renal clearance of
and diabetic retinopathy, *436
- TRANSPLANTATION**
of human neonatal pancreas, *421
islet cell, *55
and islet isografts, *419
of islets of Langerhans
and histocompatibility of endocrine tissue, 766-775
and reversal of alloxan diabetes, *420
spleen as site for, *437
survival of in non-immunosuppressed rats, *420
- isologous intraportal, *420
kidney
and glycosuria and hyperglycemia, *55-56
and oral glucose tolerance and capillary basement membrane width in related prospective donors, *434
of pancreas
into retroperitoneal jejunal loop, *604
pancreatic islet
and glomerular lesions in diabetic rats, 280-285
of pancreatic islet allografts
liver as site for, *418
and pancreaticoduodenal allografts
functional recovery of, *446
of pancreaticoduodenal isografts
long-term exocrine function of, *689
renal
and diabetic pregnancy, 497-501
- TRAUMA**
burns
and hyperglucagonemia, *694
and insulin resistance, *446
and hormone-substrate relationships, *691-692
- TRIAMCINOLONE**
and alanine-U-¹⁴C incorporation into glucose, 650-656
- TRIGLYCERIDES**
glucose conversion to
and diabetes, *437
immunoreactive gastric inhibitory polypeptide release and, 1052-1053
medium-chain
ketogenic response to in experimental hyperosmolar diabetic syndrome, 301-305
secretion
and stress, *441
and serum immunoreactive insulin
and glucose response to intravenous glucose loads, 1053-1054
- TRIS AMINO-METHANE**
and sucrose inhibition, *692
- TUBERCULOSIS**
and malignant insulinoma, 600-601
- TUMORS**
and glucose intolerance, 664-670
- growth
and immunosuppressive therapy, *243
hypoglycemia
and oral diazoxide, *431
islet cell, *693
metastatic carcinoid
and glucose intolerance, 664-670
neurofibrosarcoma
and hyperinsulinemic hypoglycemia, *1128
- TWINS**
identical
diabetes and histocompatibility antigens in, *402
identical diabetic
and metabolic and endocrine studies, *385
monozygotic, of juvenile diabetics
and glucagon secretion, *779
- UGDP PHENFORMIN STUDY**, 65-184, *397
design and methods, 66-67
life tables, 155-160
mortality results, 71-73
and blood glucose control, 91-92
after discontinuation of phenformin therapy, 114, 115, 116
after discontinuation of tolbutamide therapy, 114, 115, 117
effect of baseline differences on, 78-84
and high adherence to treatment, 88
and hypertension, 96
number and percent dead by cause of death, 71-73
statistical evaluation of, 73-78
patients, 67-71
and adherence to treatment, 86-88
baseline characteristics, 133-153
baseline characteristics by treatment groups, 119-130
baseline visual acuity measures, 126
blood glucose levels, 88-92, 124, 125
by blood pressure, 127
cardiothoracic ratio, 128
cardiovascular risk factors for, 69
characteristics before initiation of treatment, 68-71
demographic characteristics, 69, 120-121

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

- diabetes screening of, 69-70
dropouts and missed examinations, 84-86
electrocardiographic findings in, 129
and eye examinations, 100-103
by family history of diabetes or cardiovascular disease, 122
fundus abnormalities in, 128
and glucose tolerance test results, 123, 124
and heart examination results, 92-100
heart rates, 130
hypertension and hypertension treatment in, 94-96
and kidney examinations, 103-104
means and standard errors for selected response variables for, 170-175
number of, 67
peripheral vascular examinations in, 104
placebo and phenformin treated, 67-68
by race and age at entry, 120
by race and sex, 121
by relative body weight, 126
serum cholesterol levels, 105-106, 127
by serum creatinine, 127
by sex and age at entry, 120
and use of medications, 106-109
weight of, 104-105
and phenformin side effects, 109-110
and procedures for classifying information on use of medications, 177-184
purposes of, 65-66
results of, 110-111
statistical procedures, 162-168
- ULCER**
duodenal
and vagotomy, and gastrin response to insulin, *388
peptic
etiology of, 777
- UNIVERSITY GROUP DIABETES PROGRAM.** *See* UGDP Phenformin Study
- UREMIA**
glucose metabolism in
and serum calcium and parathyroid hormone, *1125
- and glucose tolerance tests
and insulin levels, *437
and insulin metabolism
and dialysis, *606
- URINE**
chromium
and diabetes, *406
creatinine
in pyelonephritic rats, 884
glucose
and diabetes screening, *430
immunoreactive insulin-like material in juvenile diabetics and normal children, 609-617
sodium, potassium, calcium, and phosphate and insulin, *1126
- UROKINASE**
and pulmonary emboli, *307
- UROKINASE INHIBITORS**
and diabetic retinopathy, 530, 531
- V**
- VAGUS NERVE**
electrical stimulation of
and gastrin release, *693
and gastric inhibitory polypeptide response to glucose, *389
and gastrin response to insulin, *388
and glucagon release, *525
stimulation
and glucagon and insulin secretion, *387
- VASCULAR DISEASE**
development
and diabetes duration, *606
and diabetes
among middle-aged male civil servants, *57
and red cell 2, 3-diphosphoglycerate levels, 724-728
and hypoglycemic agents, *see* UGDP Phenformin Study
and islet of Langerhans transplantation, 774-775
and phenformin therapy, *397
- VASCULAR SYSTEM**
and long-term juvenile diabetes, 562
- VEINS**
occlusion
fibrinolytic response to, diabetic retinopathy and, 529-533
portal
glucose and glucagon, prostaglandin E and, *430
and islet isografts, *419
portal and peripheral
and blood proinsulin, insulin, and C-peptide in normals in, *103
and insulin measurements in massive obesity, *447
- VENTROMEDIAL HYPOTHALAMUS**
stimulation
and plasma insulin and glucose, *386
- VERAPAMIL**
and inhibition of calcium influx in beta cell, *400
and inhibition of insulin release, 547-551
- VERTIGO**
and diabetes, *1126
- VIRUSES**
Coxsackie B4
and diabetes, 348, *386, *389
and diabetes etiology, 1123-1124
EMC
and induced diabetes, *779
- VISUAL ACUITY**
of UGDP study patients, 101, 126
- VITAMINS**
B-12
and phenformin-treated diabetic serum, *439
- VON WILLEBRAND FACTOR**
and platelet aggregation
and diabetes, *398
- W**
- WEIGHT**
gain
and serum triiodothyronine, *406
loss
and fasting, *242
and muscle capillary thickening
and retinopathy, 286, 287

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

SUBJECT INDEX 1975

reduction
 and exercise in obese women, *1034
 and semistarvation, *690
 and serum growth hormone levels in
 maturity-onset diabetics, 978
 in UGDP study patients, 104-105, 126
 mean values and standard errors for,
 174-175

WILSON'S DISEASE, *1128

Y

YEAST
 and glucose tolerance, *433

Z

ZOLLINGER-ELLISON SYNDROME,
 *693

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64	Supplement 2, 393-448	August, 705-784
Supplement 1, 65-184	May, 449-528	September, 785-864
February, 185-248	June, 529-608	October, 865-960
March, 249-312	July, 609-704	November, 961-1040
April, 313-392		December, 1041-1136

AUTHOR INDEX 1975

In this index are the names of authors of articles that have appeared in **DIABETES** and those whose articles have been abstracted in the **Journal** during 1975. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Subject Index appears on page 1.

A

Abbasi, A.A., *425
Abe, Hiroshi, 971-976
Abe, Ryuzo, *1128
Abell, D.A., 874-880
Aberg, Hans, *55
Abraira, C., *425
Adam, Peter A.J., *605
Adams, L.D., *409
Adour, Kedar K., 449-451
Ahmadi, H., *425
Ajlouini, Kamel, *407, 633-636
Akatsuka, Nobuharu, *56
Akgun, S., *425
Akpan, J.O., *425
Alberti, K. George M.M., *1032-1033
Albisser, A.M., *404
Aleyassine, H., *1032
Almer, Lars-Olof, 529-534
Alsever, Robert N., *605
Altzuler, N., *407
Amend, William J.C., Jr., *1125
Andersen, O. Orved, *387
Anderson, C.H., *406
Anderson, J.H., *398
Andersson, Arne, *1032
Andres, Reubin, *1126
Andrews, Samuel S., *604
Antoniades, Harry N., 997-1004
Aoki, Thomas T., *54, 463-467, *691-697
Arcangeli, Michael A., 516-522
Archer, Juanita A., *688
Ardill, J., *693
Arieff, Allen I., *241, *307, *1126-1127
Arimura, Akira, *779
Arnold, Neil I., 497-501
Aronoff, Stephen L., *402, *427
Asplund, Kjell, *400, 746-752
Assal, Jean-Philippe, 190-193, 463-467, 672-679
Assan, Roger, 791-800, *1130
Ater, Joann L., *781
Atsmon, A., 535-537
Attali, Jean Raymond, 791-800
Audhya, T.K., *385

Avioli, Louis V., *398
Ayyagari, V., *396

B

Backscheider, Joan E., *688
Baetens, Dany, *1033, *1035-1036
Bagdade, J.D., *426, *693
Bagula, R.L., *448
Ball, Margaret R., *691-692
Ballinger, Walter F., *419
Barbosa, J., *242, *308-309, *402, *434
Barker, Clyde F., *418, 766-775
Barnes, E.W., *606
Baruh, S., *426
Baskin, F., *426
Basoli, Antonio, *243
Bataille, D., *54, *395
Bataille, Pascale, *780-781
Batchelder, T., *57
Batchelor, Bruce R., *688
Bates, Robert W., *688
Battarbee, Harold D., *688
Battista, David di, *436
Baue, Arthur E., *55
Baumeister, Carl F., *426
Baur, Sonia, 801-810
Beaty, H.N., *426
Beck, Peter, *779
Behr, C., *388-389
Beigelman, Paul M., *427
Beischer, N.A., 874-880
Beischer, W., *404, 988-996
Beisel, William R., 350-353
Beisswenger, Paul J., *427
Belfiore, Francesco, 865-873
Bell, William, *307
Bennett, M.A., *309-310, *1036
Bennett, Peter H., 362-368, *402, *427, 538-546, *1036
Bennett, Richard H., *443
Bentle, L.A., *416
Beppu, Hirokuni, *56
Bergman, E.N., *1125
Bergstrom, B.H., *398
Bergstrom, W.J., *1128-1129

Bernardis, Lee L., *386
Berning, H., *54
Bernstein, Robert S., 207-213
Besser, G.M., *56-57
Bessman, Alice N., *396, *433, 724-729
Bessman, Samuel P., 724-729
Bhathena, S., *408
Bianchi, Raymond, 820-828
Bickers, D.R., *433
Bierman, Edwin L., *58
Biernat, Jerzy, *780
Bilginturan, N., *400
Birkenhager, J.C., *1127-1128
Bishop, J., *402
Bivens, Carl H., *385, 664-671
Bjorntorp, Per, *1127
Blackard, William G., *398, *604, *1034
Blackburn, George L., *692
Blacksbear, Perry J., *1032-1033
Blanks, M.C., *409
Blazquez, Enrique, *411, *1035-1036
Bleicher, S.J., *415
Blom, W., *604
Blondel, B., *605
Bloom, A., *427
Bloom, S.R., *56-57, *525
Blum, I., 535-537
Blumenthal, Stanley A., *428, 645-649
Boden, G., *408, *525
Bogden, Arthur E., *308
Bohannon, N.V., *428
Boime, I., *405
Boisseau, V.C., *398
Borden, E. Keith, *414
Borkowski, A., *691
Born, J.L., *395
Borzi, Vito, 865-873
Botstein, P., *432
Botz, C.K., *404
Boyles, R.R., *420
Braddom, R., *414
Bradley, E.L., III, *689
Bransome, E.D., Jr., *396
Braserton, W.E., Jr., *396
Braunsteiner, H., *387
Bray, G.A., *394, *436

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
Supplement 1, 65-184
February, 185-248
March, 249-312
April, 313-392

Supplement 2, 393-448
May, 449-528
June, 529-608
July, 609-704

August, 705-784
September, 785-864
October, 865-960
November, 961-1040
December, 1041-1136

AUTHOR INDEX 1975

Brazeau, Paul, *421
 Brennan, Murray F., *54, *691-692
 Brett, G.Z., *57
 Bridgman, J.F., *1033
 Brockman, Ronald P., *1125
 Brodows, Robert G., *1125
 Brooker, Gary, *394, *414, *1034
 Brown, David C., *1036
 Brown, David M., 280-285, *1128
 Brown, John C., *413, 1050-1056
 Bruce-Robertson, A., *406
 Bruns, David E., *395
 Brunzell, John D., *58, *420
 Bryce, David, 842, 850
 Buchanan, K., *693
 Buckler, J.M.H., *1033
 Buis, Anton J.M., *1127
 Bulgheroni, P., *526
 Burney, Spencer W., *402
 Burns, T.W., *428
 Burr, I.M., *399
 Burrington, John, *605
 Buse, Maria G., *415
 Busuttill, Ronald W., *689
 Butcher, D.L., 1057-1065

C

Caccamo, Anna, 758-761
 Cahill, George F., Jr., *54, *427,
 463-467, 516-522, *1035, 1123-1124
 Camerini-Davalos, Rafael A., *439, *445
 Campbell, C.J., 36-43
 Campbell, I.W., 381-384, *525, *689
 Campbell, Robert G., *1125
 Campfield, L.A., *436
 Canfield, W.K., *406
 Cantalamessa, L., *526
 Carboni, Manlio, *243
 Caren, Raymond, *241, *307
 Carlström, S., *414
 Carr, D., *56
 Carter, James R., Jr., 257-262
 Castro, Jamie H., *690
 Cataland, S., *413
 Cavagnini, F., *526
 Cavalieri, R.R., *693
 Cerasi, Erol, 746-752, 1094-1100
 Chacra, Antonio R., 1072-1080
 Chambers, Arthur L., *398, *428,
 684-687
 Chandler, James G., *689
 Chandramouli, V., 257-262
 Chang, Kam, *420
 Chapman, Barbara, *1126
 Charles, A., *419
 Charters, A. Crane, III, *689

Chaudry, Irshad H., *55
 Chen, Mei, *414, 910-914
 Chen, I-Wen, *1036
 Cherrington, Alan D., *407, *525
 Chesnokov, V.N., *388
 Chez, Ronald A., *241, *307
 Chiasson, J.-L., *403, *407, 574-584
 Chick, William L., *689
 Chihara, Kazuo, *691
 Chin, Frank T., 820-828
 Chiumello, Giuseppe, 758-761
 Chochinov, Ronald, 859-860
 Christacopoulos, P.D., *415, *437
 Christensen, Niels Juel, *55
 Christlieb, A. Richard, 190-193, *429,
 *441

Christophe, Jean, *1033
 Christy, M., *387
 Chronis, S.D., *437
 Claeys-De Clercq, P., *691
 Clain, D.J., *694
 Clark, Charles M., Jr., *410, *429
 Clark, Julia B., *429
 Clark, Julia F., *410
 Clarke, B.F., 381-384, *525, *689
 Clarke, P.V., *1034
 Claus, Thomas H., *429
 Clemens, A.H., *404
 Clements, Luther J., *689
 Clements, Rex S., Jr., *399
 Clowes, George H.A., Jr., *692
 Cohen, Margo P., *429
 Cohen, R.D., 618-624
 Colle, Eleanor, *421
 Colome, S., *57
 Colwell, John A., *398, *428, 684-687,
 *1035

Condorelli, M., 249-256
 Conlay, Lydia A., *430
 Connell, A.M., *693
 Connell, G.M., *395
 Conway, M., *604
 Cooke, C. Robert, *1126
 Cooperman, Avram M., *689-690
 Corbo, Lucille, *241, *307
 Cornblath, M., *401
 Cornog, John L., *1128
 Corral, R.J., *525
 Costin, G., *430
 Couropmitree, Chaipon, *1033
 Coy, David H., *56-57, *408, *779
 Crabbe, J., *242, *308
 Craighead, John E., *779
 Crepaldi, Gaetano, *1130
 Crockett, Samuel E., *389, *413, *525
 Crook, Lynn, *1035
 Crossley, Jeanette R., 609-617

Crudup, James W., *604
 Cryer, P.E., *412
 Cuatrecasas, P., *393
 Cudworth, A.G., 345-349
 Curnow, R.T., *430
 Czech, Michael P., *418

D

Dahlenburg, G.W., *1035
 Dahms, W.T., *394
 Damschen, G., *242, *308
 Danforth, Elliot, Jr., *406
 Danowski, T.S., 776-778
 Daughaday, William H., 859-860
 Davidoff, F., *437
 Davidson, John K., 263-271, *430
 Davidson, Mayer B., *394, *405,
 881-891, 1086-1093
 Davis, Brian, *1035
 Davis, G., 547-551, 892-901
 Davis, Paul J., *1126
 Day, J.L., *779, *1125-1126
 Dazord, Alice, *780-781
 Debartolo, M., *425
 De Belle, Ross, *389
 Debons, Albert F., *385
 DeFronzo, Ralph A., *1126
 De Hertogh, R., 983-987
 De Jesus, Pacifico V., Jr., *1126
 De Lallis, R.A., *437
 Deluca, K., *413
 Dembo, Alon J., 28-35
 De Meyts, P., *393
 De Neef, Philippe, *1033
 Derojas, Juan F., *431
 Deschodt-Lanckman, Monique, *1033
 Desmecht, P., *242, *308
 Detre, Katherine M., *385
 Devis, G., *694
 Dickerman, Richard M., *604
 Digirolamo, M., *431
 Digirolamo, Mario, *418
 Dippe, Stephen E., 362-368
 Distefano, G., 291-294
 Distiller, Larry A., 378-380
 Dobbs, Richard, *412, *604, *1033
 Dobson, Harold L., *405
 Doe, R.P., *402
 Doerner, Tom, *241, *307
 Doisy, R.J., *406, *446
 Dolger, Henry, 856-858
 Dolkas, Constantine B., 225-229, *692
 Donato, Luigi, *606
 Donohue, Maureen, *1035
 Doron, M., 535-537
 Doty, Howard E., 449-451

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Douglas, J.F., *55-56
 Douglass, John M., *690
 Drash, Allan, *401, *447
 Driessen, June F., *438
 Drillet, Francoise, *243, *309
 Duchesne, Jules, 185-189
 Duckworth, W.C., *426
 Dudl, R. James, *526
 Duga, Judith, 301-305
 Dulin, W.E., *448
 Duncan, L.J.P., 36-43, *525, *606
 Dupre, J., *413
 Durán, Tomás A., *431

E

Earp, H.S., *431
 Eaton, R. Philip, *442, 502-509,
 510-515, 523-524, *604, 1020-1026
 Edgar, P.J., *444
 Edwards, Peter, 801-810
 Eisenbud, Elliot, *431
 Eisenstein, Albert, *409
 Elde, Robert P., 230-237
 Ellenberg, Max, *432
 Ellerman, Jeanette, 476-488
 Elliott, R.B., 609-617
 Ellis, S., *57
 Engelberth, Otto, 214-224
 Ensinn, John W., 295-300, *409, *526,
 735-740
 Epstein, Michael F., *241, *307
 Ertel, N., *425
 Esber, Henry J., *308
 Eschwege, E., *397, 585-593
 Essa, N., *408
 Esterly, J., *400
 Etani, Nobuaki, 971-976
 Etzwiler, Donnell D., *446
 Ewart, Robin L., *436, 705-714
 Ewing, D.J., 381-384
 Ezequiel, M., 637-640

F

Fain, John N., *690
 Fajans, Stefan S., 44-53, *410, 452-462
 Falko, J., *413
 Faloona, Gerald R., *56, 313-316, *412,
 *604, *694, *1033, *1126
 Fanska, Rudolph E., 272-279, *690
 Fechner, W., *242, *308
 Fedele, Demenico, *1130
 Feinman, Lawrence, *691
 Felber, Jean P., *413, *435
 Feldman, Jerome M., *385, *432,
 664-671, *1126
 Felig, Philip, *385-386, *406, 468-475,
 730-734, *1128

Fenton, Lawrence, *1036
 Fernandes, J., *604
 Fernandez-Cruz, A., *414
 Ferrendelli, J.A., *405
 Field, William E., 1041-1049
 Fineberg, S. Edwin, *432, *443
 Finkel, Richard M., *441
 Finkowski, Michael, *607
 Finucane, J.F., 829-832
 Fiser, Robert H., Jr., *604-605, *1036
 Fisher, Delbert A., *604-605
 Fisher, J.N., *413
 Fitzgerald, M.G., *309-310, *1036
 Fleck, Henry, *445
 Fleischman, Alan R., *241, *307
 Forgue, Marie-Elisabeth, 715-723
 Forsham, Peter H., *241-242, *308,
 *411, *421, *690, *779-780
 Fort, P., *432
 Frahm, H., *389
 Frankel, Barbara J., 272-279
 Franklin, A., *437
 Franks, G., Jr., *433
 Fraser, T.R., *1034
 Freiberg, J.M., *433
 Freinkel, Norbert, *400, *1033
 Freychet, Pierre, *54, *395, 566-573,
 715-723
 Friedman, Maryanne, *1036
 Friedman, Sandor A., *1126
 Friesen, Henry G., *309
 Froberg, S.O., *1033
 Frohman, Lawrence A., *386, *417
 From, Annette, *385
 Fujita, Yoshikuni, 17-27, *410, 552-558,
 1072-1080
 Fulop, Milford, 594-599, 785-790
 Fulton, Robert L., *605
 Funderburk, Cullie, 842-850
 Furuyama, Takashi, 1066-1071
 Fussganger, R.D., *393

G

Gabbay, K.H., *398, *413
 Gabbiani, G., *605-606
 Gagliardino, Juan José, *1129
 Gamble, D.R., *386, *427
 Ganda, O.P., 354-361, *428, *433
 Gander, R.E., *404
 Gandhi, V.S., *415
 Gannon, Mary C., *242, *308-309, *394,
 *1128-1129
 Garber, A.J., *412, *525
 Garcia, J.F., *395
 Gardiner, Robert J., *1032
 Gardner, R., *425

Gargantini, Luigi, 758-761
 Garland, D., *433
 Garlaschi, Cristina, 758-761
 Garrison, Mary M., *688
 Gasparo, M. de, 983-987
 Gavareski, David J., *58
 Genuth, Saul M., *690
 Geokas, Michael C., *55
 George, William J., *689
 Gerich, John E., *241-242, 272-279,
 *308, *411, *428, *690, *779-780
 Gerritsen, George C., 272-279, *409
 Gershberg, Herbert, *434
 Gerstenhaber, Brett, 594-599
 Gibson, K.D., *385
 Gigger, Mardi, *1036
 Ginsberg, B., *393
 Ginsberg, H., *396
 Ginsberg-Fellner, Freda, 856-858
 Girard, Jean Raymond, 791-800
 Giustina, G., *526, *1033-1034
 Gleason, R.E., 354-361, *386, *433,
 *445, 672-679
 Godfrey, D.A., 1081-1085
 Goetz, Frederick C., *55, *402, *434,
 497-501
 Gold, Ernest M., *447
 Goldman, Hy, *421
 Goldman, Leonard I., *780
 Goldman, Ralph F., *406
 Goldman, Stuart, 600-603
 Goldstein, S., *441
 Gonzalez, A., *57
 Goodman, A.D., *446
 Goodman, J., *396, *433
 Gorden, Phillip, 362-368, *402, *688,
 *1036
 Gordienko, O.E., *388
 Gordon, Edwin E., 301-305, *407
 Gordon, Jack, 600-603
 Gossain, Ved V., 833-835
 Gottesbüren, H., *388-389
 Gottlieb, B., *407
 Gotto, Antonio M., 552-558
 Grant, Neville, 207-213
 Grasso, S., 291-294
 Greenberg, G.R., *406
 Greene, Douglas A., *1126
 Greenwood, M.R.C., *419
 Greenwood, R.H., 1027-1031
 Grey, Neil J., 10-16
 Grgic, Ante, 820-828
 Griffith, Rogers C., *419
 Grill, Valdemar, 746-752
 Grodsky, Gerold M., 272-279, *399,
 *419, *690
 Grossman, William K., *431

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Grubb, R.L., Jr., *1129
 Guercio, Maria Jose del, 758-761
 Guerra, S., *396
 Gugliucci, C., *439
 Guillemin, Roger, *241-242, *308,
 *779-780
 Guisado, Raul, *1126-1127
 Gustafson, Gail, *411, *779-780
 Guthrie, D.W., *400, *434
 Guthrie, R.A., *400, *434
 Gutzeit, Arndt, 1094-1100
 Guyot, C., *397
 Gwinup, Grant, *1034

H

Habnel, Robert, *1033
 Haff, Roderick C., *693
 Hagen, Thad C., *407, 633-636
 Hagg, S.A., *415
 Haist, R.E., *403
 Hales, C. Nicholas, *779
 Hall, R., *56-57
 Halperin, Mitchell L., 28-35
 Halter, J., *414
 Hamby, Robert I., *242, *691
 Hamilton, B., *401
 Hamilton, C.A., 618-624
 Hamilton, P.J.S., *57
 Hamlin, Clive R., 902-904
 Hamman, R.F., *434
 Hammond, James M., 1011-1019
 Hampers, C.L., *1125
 Hampshire, J., *407
 Hane, Satoshi, *779-780
 Hanover, B., *439
 Hansen, Aage Prange, 977-982
 Hanson, Richard W., *780
 Hardy, M., *419
 Hargis, Gary K., *58
 Harris, E., *243, *412
 Harris, Virginia, *427
 Harrison, J., *410, *442
 Harrower, A.D.B., *525
 Haubert, Richard E., *781
 Hauer, B.S., 350-353
 Hauhart, Richard E., Jr., *417
 Havel, R.K., *417
 Hawkins, B.S., *397
 Hawkins, W. Rex, *435
 Hayakawa, Hiroyuki, 1-9
 Hayes, R., *693
 Hayes, T.M., *427
 Haymond, Morey W., 369-372, *412,
 *692, 961-970
 Hazen, R., *394
 Heding, L., *412

Hedo, Jose A., *411
 Hedstrand, Hans, *55
 Hefland, A.E., *435
 Hegre, Orion D., *419, *435
 Heinemann, M., *426
 Heinze, E., 373-377
 Hellerstrom, Claes, 746-752
 Hellman, Bo, *308, *1033, *1127
 Henderson, M.J., *403
 Hendler, Rosa, *406, 468-475
 Henquin, Jean-Claude, *1127
 Henry, John B., *526
 Heptner, Wolfgang, *413, *435
 Herchuelz, A., *400
 Hermann, Robert E., *689-690
 Herold, Arthur A., Jr., *430
 Herron, Arthur L., Jr., 17-27, 1072-1080
 Hertelendy, Frank, 842-850
 Heuclin, Christine, 791-800
 Hicks, T., *605
 Higdon, Gary, *410
 Hill, Claire M., *55-56
 Hill, Donald E., *436
 Hoberman, Henry D., 785-790
 Hofmann, Klaus, 776, 778
 Hohl, R.D., *436
 Hollis, J., *414
 Holloway, Paul A.H., *1032-1033
 Hollows, F.C., *386
 Holmes, William L., *1035
 Honjo, I., *242-243, *309
 Hope-Gill, H., *1034
 Horigome, Ken, 811-819
 Horton, Edward S., *406, *439
 Horwitz, David L., *401, *403, *1033,
 *1034
 Hoshi, Mitsuru, *694-695, 971-976
 Hover, Barbara A., 369-372, *440,
 476-488, 489-496, *526, *692
 Howard, Charles F., Jr., 201-206
 Hsu, Chung-Yi, *414, *1034
 Hsu, Tah-Hsiung, 559-565
 Huang, L.C., *394
 Huang, S.W., *401
 Huff, T.Z., *396
 Huhti, E., *388
 Hulse, Mildred, *433
 Hultman, E., *1033
 Hunter, W.M., *525
 Hurukawa, Yotaro, *1036
 Hutcheson, Donna R., *694
 Hutchinson, Donald L., *241, *307
 Hutton, J.C., *386

I

Imagawa, W., *419

Imawari, Michio, *56
 Imura, Hiroo, *691
 Inoue, S., *436
 Ireland, J.T., 1027-1031
 Irvine, W.J., 36-43, *606
 Ishibashi, Miyuki, *56
 Ishii, Shoji, 811-819
 Issekutz, Bela, Jr., 915-921
 Izumi, Kanji, 971-976

J

Jackson, James A., *310
 Jackson, R.L., *400, *434
 Jackson, W.P.U., *310, 851-855
 Jain, Kanti, *403
 James, R., *400
 Jarrett, Leonard, *395, 1011-1019
 Jarrett, R.J., *57
 Javorski, C., *396
 Jeanloz, Dorothy A., *1035
 Jeanloz, Roger W., *1035
 Jeeheebho, K.N., *406
 Jefferson, Leonard S., *416
 Jeffrey, P., *1035
 Jen, Phyllis, *1129
 Jennings, A.S., *403, *407
 Jerums, G., *436
 Joffe, B.I., 378-380
 Johansen, K., *386
 Johnson, David G., *409
 Johnson, Jennifer, 801-810, *1129
 Johnson, Patricia R., *688
 Jones, Calvin E., *605
 Jones, D.H., 1027-1031
 Jones, Elizabeth M., *781
 Joosten, Harrie F.P., *386-387, *1127
 Jordan, Jennifer, 36-43
 Joyce, M. Patricia, *403
 Joyce, Thomas, *1036
 Juhn, D., 753-757

K

Kahkonen, D.M., *436
 Kahn, C.B., 354-361
 Kahn, R., *383
 Kalhan, Satish C., *605
 Kalk, W.J., *310, 851-855
 Kamdar, Vikram V., *437
 Kamm, Donald E., *525-526
 Kaneto, Akio, *56, *387
 Kanter, Yoram, 724-729
 Kao, Race, *780
 Kaplan, S.A., *394

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Karam, John H., *241-242, *308, *411, *428
 Karamanos, B.G., *415, *437
 Kardatos, C.G., *415
 Karl, Irene, 10-16
 Karl, R.C., *405
 Kastin, A., *56-57
 Kato, Yuzuru, *691
 Katsilambros, Nicholas, 190-193
 Kaufmann, R.L., 672-679
 Kavanagh, Terry, *56
 Kawai, Kohzo, 1-9
 Kawamori, Ryuzo, 971-976
 Kazemi, H., *781
 Keen, Harry, *57
 Keenan, William, *1036
 Keller, P., 851-855
 Kellner, Hans M., *435
 Kelly, Paul A., *309
 Kemmler, Wolfgang, *693
 Keup, U., *692
 Keusch, G., *58
 Kew, M.C., 286-290
 Kewenter, J., *693
 Keymolen-Jardini, V., *691
 Kikkawa, R., 1057-1065
 Kikuchi, Masakuni, *1037
 Kim, S., *445
 Kimmerling, G., *396
 King, L.E., Jr., *444
 King, S., *399
 Kipnis, David M., 10-16, 207-213, *412, *420, 705-714
 Kissebah, A.H., *1034
 Kitabchi, A.E., *396, *426
 Kjeldsen, Henning, 977-982
 Klein, L., 1057-1065
 Klimt, C.R., *397
 Knatterud, G.L., *397
 Knopp, Robert H., *607
 Knowles, Harvey C., Jr., 833-835
 Koffler, Herbert, *1036
 Kogut, C. Hyman, *430
 Kohn, Robert R., 902-904
 Koide, T., *404
 Kolanowski, J., *242, *308
 Kolendorf, Klaus, *691
 Koncz, L., *437
 Konturek, Stanislaw J., *780
 Kornfeld, Stuart, 705-714
 Korsten, Mark A., *691
 Kosaka, Kinori, *56, *387
 Kozak, George P., 190-193, 463-467, *695
 Kramer-Blankestijn, M., *1127-1128
 Kreitzer, Stephen M., 594-599
 Krimsky, Isodore, *385
 Krotkiewski, Marcin, *1127

Kuchmy, Barbara L., *525-526
 Kulkosky, P., *414
 Kumar, Dinesh, *437
 Kupiecki, F.P., *409
 Kuzuya, H., *401
 Kwiecien, Nina, *780

L

Labrie, Fernand, *1033
 Lacroix, Marcel, 185-189
 Lacy, Paul E., *400, *419, 658-663, 836-841
 Lacy, W.W., *407, 574-584
 L'age, M., *242, *308
 Laimins, Marta, *398, *428, 684-687, *1035
 Laimaire, Francois, 791-800
 Lamb, P., *309-310
 Lambert, Andre E., *1127
 Lamberts, S.W.J., *1127-1128
 Landahl, H.D., *399
 Landor, J.C., *408
 Langholz, J., *242, *308
 Langley, P.E., *428
 Lardy, H.A., *416
 Larner, Joseph, *394, *414, *781, *1034-1035
 Laron, Z., 535-537
 Larson, K.B., *1129
 Lassman, M.N., *414
 Lauris, Vilma, *689
 Lavis, Victor R., 238-239
 Lawrence, J.H., *395
 Lazarow, Arnold, *419, *435
 Lazarus, J. Michael, *1125
 Lazarus, Norman R., *1035
 Lebovitz, Harold E., 664-671
 Le Cam, Alphonse, 566-573
 Lee, Harvey B., *437
 Lee, Sun, *689
 Lefebvre, Pierre J., 185-189, *387
 Lefkowitz, Robert J., *780
 Leibel, B.S., *404
 Leibovici, D., *439
 Leichter, Steven B., *412, 1005-1010
 Lemaire, J.R., 672-679
 Lenoir, Pierre, 566-573
 Lenzi, Silvia, *606
 Leonard, Robert J., *419, *435
 Lepp, A., 637-640
 Lerner, Roger L., *419, *438
 Lernmark, A., *399
 Leshin, Stephen J., *694
 Levin, Marvin E., *398
 Levin, Seymour R., *438, *691
 Lev-Ran, Arie, *605
 Levy, J., *400

Lewis, Richard P., *525
 Lewis, S.B., *448
 Li, Jeanne B., *416
 Libertino, John A., *441
 Lieber, Charles S., *691
 Liechty, R. Dale, *605
 Lifshitz, F., *432
 Like, Arthur A., *421, *689
 Liljenquist, J.E., *403, *407, 574-584
 Lin, B.J., *403
 Lind, T., *56-57
 Lindsey, C. Alfred, *56, 313-316, *694
 Liu, Francis, 801-810, *1129
 Lloyd, M.H., 618-624
 Loewenstein, Joseph E., *430
 Logothetopoulos, John, 194-200, *403
 Lomedico, Peter T., *405
 Lopez-Habib, Gabriel, 185-189
 Lopez-S., Alfredo, *604
 Lorenzi, Mara, *241-242, *308, *411, *428, *690, *779-780
 Lo Vecchio, Luigi, 865-873
 Lowrie, Edmund G., *1125
 Ludvigsen, Carl, Jr., *444
 Lundbaek, Knud, 977-982
 Luschin, Jean H., 902-904
 Luyckx, Alfred S., 185-189, *387
 Lyall, Santokh S., *1128
 Lynch, Richard G., *243
 Lyngsoe, J., *387

M

Ma, King W., *1128
 McClaren, M.J., 286-290
 MacCuish, A.C., 36-43, *606
 McDaniel, Huey G., *438
 McDaniel, Michael L., *400, *444, 836-841
 McDonald, Jay M., *395
 MacDonald, M.J., *416
 McDougal, D.B., Jr., 1081-1085
 Mc Evoy, J., *55-56
 McGeown, Mary G., *55-56
 MacLaren, N., *401
 McMillan, Donald E., *438, 944-957
 McMonagle, James, *1128
 Mahler, R.F., 1027-1031
 Mahler, Richard J., *688
 Mako, Mary E., *413, *1034
 Makous, W., *414
 Malaisse, W.J., *400, 547-551, *694, 892-901
 Malaisse-Lagae, F., *605, *694, 892-901
 Malins, J.M., *309-310, *1036
 Mallinson, C.N., *56-57
 Manning, Michele, *690

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Manougian, E., *395
 Manzano, Francisco M., 463-467
 Marco, Jose, *411
 Margo, S.L., *431
 Margolis, S., *393
 Marieb, Norman J., *1128
 Martinan, Barbara, *397, 680-683
 Marliiss, Errol B., 28-35, *404, *406
 Marosi, Judit, *526
 Marsh, David, *525
 Martin, Arline L.A., *439
 Martin, D.B., *397
 Martin, Duane M., *526
 Martin, F.I.R., *606, *1035
 Martin, Julio M., *436
 Martin, Malcolm M., *439
 Martinson, Donald R., *407, 633-636
 Maruhama, Yoshisuke, *1128
 Masler, Donald S., *1128
 Massry, Shaul G., *241, *307
 Matas, A.J., *421
 Matschinsky, Franz M., 369-372, *405,
 *440, 476-488, 489-496, *526, *692,
 961-970, 1081-1085
 Matsuzaki, Shohei, *691
 Mauer, S. Michael, 280-285
 Max, Stephen R., *387-388
 Mayes, Susan, *436
 Mazzaferrri, E.L., *413
 Meguid, Michael M., *691-692
 Meinert, C.L., *397
 Meissner, C., 988-996
 Meissner, H.P., *387
 Mellow, Mark, *389
 Menahan, L.A., 926-932
 Menefee, Max, 286-290
 Menninger, Florian F., Jr., *308
 Menzel, P.H., *525
 Merimee, Thomas J., *692
 Merrill, John P., *1125
 Mertvetsov, N.P., *388
 Messina, A., 291-294
 Metzger, Boyd E., *407, 1032, *1033
 Michael, Alfred F., 280-285
 Michas, Constantine, *447
 Miki, Eishi, *387
 Miller, Leona V., *437
 Miller, Max, 362-368, *434, *442,
 538-546, *1036, 1057-1065
 Miller, Ralph E., *403, *439
 Miller, Richard E., *416
 Mintz, Daniel H., *241, *307
 Miwa, Ichitomo, *404, *526
 Modlinger, R., *425
 Moerman, E., *441
 Molenaar, Donald M., *401
 Moller, Birger Broch, *691
 Mondon, Carl E., 225-229, *692

Moore, Francis D., *691-692
 Moore, Marilyn, *310
 Moorhouse, J.A., *437
 Mörchen, R., *242, *308
 Morera, Anne M., *780-781
 Morgan, Howard E., *780
 Morley, John E., 378-380
 Mortimer, C.H., *56-57
 Mosora, Florentina, 185-189
 Moss, James M., *439
 Motto, George S., 922-925
 Mouawad, E., *691
 Moule, M., *441
 Moylan, J.A., *694
 Muggeo, Michele, *1130
 Müller, Walter A., *54, *691-692
 Mulrow, P.J., *414
 Munoz, L., *411
 Murad, F., *394
 Muramoto, Shingo, 1-9
 Murphy, Barbara F., *692
 Murray, Harry M., *693

N

Nagai, Katsuya, *417
 Nagel, Theodore C., *1033
 Nair, R.M.G., *398
 Najarian, John S., 280-285, *421,
 *446, 497-501
 Naji, A., *418
 Nakamoto, Yasushi, 1-9
 Nakhooda, A.F., *406
 Nanbu, H., *242-243, *309
 Napoli, Elena, 865-873
 Natale, Berardo di, 758-761
 Nathans, A.H., *399
 Navalesi, Renzo, 317-327, *606
 Nelson, P.G., *402
 Nerup, J., *387
 Nervi, F.O., *57
 Neville, Edwin C., *1128
 Nicholson, John F., *1128
 Nierle, C., 373-377
 Niki, Atsushi, *403, *404, *526
 Niki, Hatsumi, *403, *404, *526
 Nikkila, Esko A., 933-943
 Nilsson, L. H:son, *1033
 Nilsson, Inga Marie, 529-534
 Nishikawa, Mitsuo, *1130
 Nizet, Alphonse H., *387
 Nolan, C.M., *426
 Norfleet, William T., 961-970
 Noth, R.H., *414
 Noval, Joseph, *420
 Nuttall, Frank Q., *242, *308-309, *394,
 *1128-1129

O

Oakes, Gary K., *241, *307
 Obando, Marcelo, *420
 O'Connor, M.D.L., *399
 Oehme, J., *242, *308
 Oh, Changyul, 856-858
 Oh, William, *604-605, *1036
 Ohgo, Shozo, *691
 Ohneda, Akira, 811-819, *1128
 Ohtsuki, Masao, *1128
 Okuda, Jun, *404, *526
 Okuyama, Makio, *1037
 Olefsky, Jerrold M., *57, 225-229, *393,
 *396, *606, *692, 801-810, *1129
 Oleksy, Jan, *780
 Oliver, I.M., 337-344
 Oliver, John R., *409
 Oppermann, Werner, *439, *445
 Orci, Lelio, *395, *605, *607, *694,
 892-901, *1033, *1035-1036
 Orellana, K., *54
 Orloff, Marshall J., *689
 Ortega, J., *430
 Osborne, R.K., *397
 Owen, Oliver E., *408, *525, *606-607,
 *780
 Owens, J., *431
 Ozawa, K., *242-243, *309

P

Pace, Caroline S., *440, 476-488,
 489-496
 Paddock, Richard J., *689
 Pagan, H.J., *448
 Pagliara, Anthony S., 369-372, *412,
 *440, *526, *692, 961-970
 Palazzolo, M., *444
 Palmer, Jerry P., 295-300, *526, 735-740
 Palmer, Warren K., *57
 Palumbo, P.J., *401, *440
 Pandit, Veena, *56
 Pandolfi, Maurizio, 529-534
 Panerai, A.E., *1033-1034
 Papagiannes, Elaine, *443, 922-925
 Papoz, L., 585-593
 Pascucci, I., 249-256
 Patel, D.G., *440
 Patel, Mulchand S., *780
 Patrassi, Neri, *243
 Patsch, J.R., *387
 Pattenian, Harry, *385
 Paul, M., 851-855
 Paul, Pavle, *1035
 Pav, Jaroslav, 214-224
 Paz-Guevara, Aldo T., 559-565
 Peach, Michael J., *414, *1034

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Peale, Augustin, *420
 Pederson, Raymond A., 1050-1056
 Pek, Sumer, *410, 861
 Pekarek, R.S., 350-353
 Penhos, J.C., *418, 637-640
 Pentecost, B.L., *309-310, *1036
 Peracchi, M., *526, *1033-1034
 Perez, G., 249-256
 Permutt, M. Alan, *405, *412, 1005-1010
 Perrino, P., *408
 Persson, G., *414
 Pessacq, Maria Teresa, *1129
 Peterson, James D., *693
 Peterson, Walter, Jr., *389
 Pfeiffer, E.F., 373-377, *404, 988-996
 Phelps, Dale L., *604-605
 Phelps, M.E., *1129
 Philipps, Ervin, *389
 Phillips, L.S., *407
 Pictet, R., *421
 Pilkis, Simon J., *429, *448
 Piló, Alessandro, 317-327, *606
 Pinto, M., *526, *1033-1034
 Pipeleers, D., *420
 Pipeleers-Marichal, M., *420
 Pi-Sunyer, F. Xavier, *445, *1125
 Piters, K., *396
 Platz, P., *387
 Plonk, James W., 664-671
 Plumer, M., *434
 Poapst, Mary, 263-271
 Podolsky, Stephen, *402
 Polk, Hiram C., Jr., *605
 Poole, Barbara L., *399
 Policova, Zdenka, *444
 Porte, Daniel, Jr., *58, *408, *414, *693, 905-909, 910-914
 Posner, Barry I., *309
 Potter, D.E., *57
 Poulsen, J.E., *387
 Power, L., *425
 Pozefsky, T., *444
 Pramanik, Arun, *1036
 Pruitt, B.A., *694
 Pulini, M., *433
 Puls, W., *692
 Pyke, D.A., *402

Q

Quick, William W., *440

R

Rabinovitch, Alexander, 1094-1100
 Rabuazzo, Agata M., 865-873

Racasa, Z., *411
 Rado, Janos P., *526
 Raichle, M.E., *1129
 Raiha, Niels C.R., 1101-1112
 Rajkumar, K.V., *55-56
 Rall, Theodore W., 650-657, 1101-1112, 1113-1122
 Ramey, E.R., *418, 637-640
 Rango, F., 249-256
 Rannels, D. Eugene, *780
 Rao, Narasimha, *420
 Raskin, P., *410, *434
 Ravazolla, M., *694, 892-901
 Ravindranath, Cheriya, *441
 Rawat, A.K., 926-932
 Rayfield, E.J., 350-353, *433
 Reaven, Gerald M., *57, 225-229, *396, *606, *692, *693-694, *1129
 Recant, L., *408
 Reckard, C.R., *418
 Reemtsma, K., *419
 Regen, David M., *448
 Rehfeld, J.F., *388
 Reichle, Frederick A., *397, *420, *1129
 Reichle, Rose Marie, *420
 Reid, D.D., *57
 Reidler, G.F., *58
 Reitano, G., 291-294
 Renold, Albert E., 1094-1100
 Reschini, E., *526, *1033-1034
 Reuben, David, *430
 Rey, Francoise, *243, *309
 Rey, Jean, *243, *309
 Reyes, Jose C., *431
 Rhee, Chung K., *431
 Rhoten, William B., *399
 Richardson, Brian P., 836-841
 Rifkenberck, David H., *387-388
 Rinderknecht, Heinrich, *55
 Ritts, Roy E., Jr., *401
 Rivier, Jean, *241-242, *308
 Rivlin, Richard S., *606
 Robberecht, Patrick, *1033
 Robertson, R. Paul, *58, *420, *441
 Rodger, N.W., *441
 Roman, D., *412
 Rose, Geoffrey, *57
 Rosen, S.M., *1033
 Rosenblatt, Andrew, 594-599
 Rosenbloom, Adrian L., *441, 753-757, 820-828
 Rosenbloom, E., *441
 Rosenfield, R.L., *401
 Ross, G., *408
 Ross, S.A., *413
 Rosselin, G.E., *54, *395, 585-593
 Rossini, Aldo A., *404, 516-522, *1035

Roth, Jesse, 362-368, *393, *688
 Rubalcava, Boanerges, *1035-1036
 Rubenstein, Arthur H., *403, *413, 753-757, *1033, *1034
 Ruderman, N.B., *415
 Rushforth, Norman B., 362-368, 538-546
 Russell, Joan, *1035
 Russell, R.C.G., *525
 Ryan, N. Thomas, *692
 Ryder, L.P., *387

S

Saathoff, J., *400
 Sacca, L., 249-256
 Sadoff, Leonard, 600-603
 Saez, Jose M., *780-781
 Sagel, Julius, 378-380, *1035
 Sailer, S., *387
 Sakurai, H., *1033
 Salganik, R.I., *388
 Salsas, Eduardo, *781
 Salzmann, H., *242, *308
 Samols, E., *410, *442
 Sampson, L., *447
 Sandek, Christopher D., *607
 Santiago, Carlos R., *431
 Santiago, J.V., *412
 Sapir, D.G., *606-607
 Sarji, K.E., *398
 Sasaki, Hideo, *1033, *1035-1036
 Sato, Haruko, *779
 Sato, Tokutaro, 1066-1071
 Savage, Peter J., 362-368, *427, *442, *1036
 Sawazaki, Norio, *1130
 Sayeed, Mohammed M., *55
 Schade, David S., *442, 502-509, 510-515, *604, 1020-1026
 Schally, Andrew V., *56-57, *408, *779
 Scharp, David W., *419
 Schatz, H., 373-377
 Schersten, B., *414
 Schiavo, Donald M., 1041-1049
 Schless, Guy Lacy, *443
 Schmelz, H., *387
 Schmid, M., *58
 Schmidt, R.E., 1081-1085
 Schmitt, Robert V., *435
 Schmitz, Jacques, *243, *309
 Schneeberger, E.E., *398
 Schneider, A.J., *433, *443
 Schneider, G., *425
 Schneider, Louis E., *58
 Schneider, Stephen H., *432, *443
 Schneider, T.R., *433
 Schneider, Victor, *241-242, *308, *690

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

Schofield, P.J., *386
 Scholl, Harold P., *58
 Schroder, K.E., 988-996
 Schubert, Harold E., 1050-1056
 Schulman, Robert H., *1126
 Schwartz, Alan L., 650-657, 1101-1112, 1113-1122
 Schwartz, Peter L., *1129
 Schwartz, Robert, *605
 Searle, E.L., *693
 Searle, G.L., 741-745
 Seftel, Harold C., 286-290, 378-380
 Selberg, W., *54
 Seltzer, Holbrook S., 17-27, *420, 1072-1080
 Semenova, L.A., *388
 Sener, A., *400
 Shafrir, Eleazar, *416
 Shah, Jayendra H., *443, 922-925
 Shames, D., *693
 Shank, Richard D., 230-237
 Shaw, Laurence, *385
 Shaw, William A.S., 915-921
 Shephard, Roy H., *56
 Sherman, Lawrence, *242, *426, *691
 Sherwin, R., *406
 Shibata, Atsumi, *444
 Shichiri, Motoaki, 971-976
 Shield, Charles F., III, *693
 Shigeta, Yukio, 971-976
 Shima, Kenji, *1130
 Shimizu, Masahiko, 1-9
 Shinoda, Akira, 1-9
 Shiu, Robert P.C., *309
 Sholiton, Leon J., 833-835
 Shreeve, Walton W., *694-695
 Shu, Michael, *427
 Shuman, Charles R., 306, *397, *420, *1129
 Simmons, Richard L., 497-501
 Simon, James D., 997-1004
 Sims, Ethan A.H., *406
 Sinclair-Smith, B.C., 574-584
 Singh, Harbhajan, *397, 680-683
 Singh, Sant P., *440
 Siperstein, M.D., *434, 741-745
 Sirek, Anna, *444
 Sirek, O.V., *444
 Sirinek, Kenneth R., *389
 Sivak, Michael V., *689-690
 Sivitz, M.C., *408
 Sjostrom, Lars, *1127
 Sloan, J.M., 337-344
 Slonim, A.E., *399
 Smith, C.L., *693
 Smith, Jo Ellen, *436
 Smith, Phillip H., *408, *441
 Smith, Robert M., *395

Smith, S., *408
 Smith, S.R., *444
 Smith, T.M., *398, *433, *445
 Smith, Ulf, *1127
 Soeldner, J. Stuart, *54, 354-361, *386, *404, *445, 672-679, *1125
 Soler, N.G., *309-310
 Solomon, S.S., *444
 Somers, G., 547-551, *694, 892-901
 Sorenson, Robert L., 230-237
 Sotaniemi, E.A., *388
 Sperling, Mark A., *411, *604-605, *1036
 Spitzer, J.J., *398
 Spring, Maxwell, *445
 Spritz, Norton, *397, 680-683
 Sramkova, Jarmila, 214-224
 Srikant, C.B., *1035-1036
 Srivastava, Laxmi, 833-835
 Stachura, Max E., *386
 Stadil, F., *388
 Starr, Jerome I., 753-757, *1034
 Staub, Nielson L., *387
 Stefanini, Paride, *243
 Steffes, Michael W., 280-285, *421
 Steichen, Jean, *1036
 Steinberg, Arthur G., 538-546
 Steinberg, Daniel, *416
 Steinberg, Steven M., *1125
 Steiner, Donald F., *399, *693
 Steiner, George, 263-271
 Steinke, Jurgen, *427
 Stelling, M., *401
 Stern, Judith S., *688
 Stern, K., *443
 Sternberg, James, *430
 Stillings, Susan N., 369-372, 476-488, 489-496, *526, *692
 Storck, Gunnar, *689
 Stout, Robert W., *58
 Strack, Inge, *409
 Streeten, D.H.P., *428, *433
 Strohmeier, G., *388-389
 Strobe, Gerald L., *525-526
 Strub, Robert, *1036
 Sudilovsky, O., 1057-1065
 Sullivan, B.H., Jr., *689-690
 Summerskill, J., *1033
 Susa, J.B., *416
 Sutherland, David E.R., 280-285, *421
 Suzuki, Hidero, *56
 Suzuki, Tadao, 190-193
 Svegaard, A., *387
 Swenson, Robert S., *693-694
 Szabo, Andrew J., 328-336, *417
 Szabo, Olga, 328-336, *417, *445
 Szende, Laszlo, *526

T

Tadaki, Hiroshi, *1128
 Tagatz, George E., 497-501
 Tager, Howard S., *693
 Tai, Tong-Yuan, *410
 Takacs, Frank J., *441
 Takazakura, Eisuke, 1-9
 Takeuchi, Jugaro, 1-9
 Tan, M.H., *417, *445
 Tanaka, Ryochi, *1130
 Tantibedhyangkul, P., *445
 Tarui, Seiichiro, *1130
 Taskinen, Marja-Riitta, 933-943
 Tattersall, Robert B., 44-53, *58, 452-462, *779
 Tavassoli, Fattaneh A., *243
 Taylor, G., *401
 Taylor, K.W., *389
 Taylor, S.I., *415
 Tchobroutsky, G., *397
 Ter-Pogossian, M.N., *1129
 Tersigni, Roberto F., *446
 Thomford, Niel R., *389
 Thompson, D., *431
 Thomsen, M., *387
 Thum, Ch., *404, 988-996
 Thurston, Jean Holowach, *417, *781
 Tiengo, Antonio, *1130
 Timmermans, H.A.T., *1127-1128
 Tipton, Charles M., *57
 Tiwary, Chandra M., 820-828
 Tobias, C.A., *395
 Todd, Herbert, 842-850
 Toledo-Pereyra, Luis H., *446
 Torklus, D.V., *389
 Tountas, C.D., *415, *437
 Trehern, Margie S., *418
 Trowell, H.C., 762-765
 Tsalikian, E., *411
 Tsang, Reginald C., *1036
 Tulloch, B.R., *1034
 Tuman, R.W., *446
 Tunbridge, W.M.G., *56-57
 Turcot-Lemay, Lucile, 658-663
 Turcotte, Jeremiah G., *604
 Turfus, Ian M., *1129
 Turinsky, J., *446
 Turnberg, L.A., *605
 Turner, R.C., *243, *412
 Turtle, J.R., 625-632
 Twiest, Melvin W., *604
 Tyler, Jean M., *446
 Tyson, John E., *692
 Tyson, R. Robert, *397, *1129
 Tzagournis, Manuel, *525

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136

AUTHOR INDEX 1975

U

- Underwood, L.E., *431
 Unger, Roger H., *56, *310, 313-316,
 *389, *410, *411, 552-558, *604,
 *607, *694, *1033, *1035-1036

V

- Valdivieso, V.D., *57
 Valleron, A.-j, 585-593
 Valverde, I., *412, *1033
 Vanderheyden, I., 983-987
 van der Kroon, Piet H.W., *386-387,
 *1127
 Vandeweghe, Mark, *58
 Van Laer, E., *691
 Van Obberghen, E., 547-551, *694,
 892-901
 Van Thiel, David H., *389
 Vasquez, E., *425
 Vaughan, N.J.A., *525
 Vermeulen, Alex, *58
 Vertes, Victor, *690
 Victor, Carl, *445
 Videbaek, Jorgen, *55
 Vigneri, R., 317-327
 Vigo, R., 291-294
 Villalpando, Salvador, *401, *447
 Villanueva, Maria L., *411
 Vinicor, Frank, *410, *429
 Vinik, A.I., *310, 851-855
 Vogt, Carlyn A., *429
 Volk, Bruno W., *447
 Voyles, N., *408
 Vranic, Mladen, *408, *525
 Vydelingum, N., *1034
 Vymetal, Frank J., 1041-1049

W

- Wagle, S.R., *447
 Wagner, W., *433
 Wahren, John, 468-475, 730-734
 Waiches, H., *434
 Waid, Thomas H., *403
 Walberg, Clifford B., *55

- Walker, Charles, *389
 Wallin, J.D., *448
 Walter, Robert M., *526, 735-740
 Walter, Robert M., Jr., *431, *447
 Walton, B., 618-624
 Wannemacher, R.W., Jr., 350-353
 Ward, J., *425
 Warne, G.L., *606
 Watkins, Dudley T., *310
 Weber, C., *419
 Weber, Hans E., *405
 Weigand, Dorothy A., *415
 Weindling, Howard, *526
 Weir, S. Bonner, *421
 Weisinger, Jose, *693-694
 Weiss, Steven, *1126
 Weissman, Robert, *55
 Welch, M.J., *1129
 Wellmann, Klaus F., *447
 Werk, Emile E., 833-835
 Weser, Elliot, *695
 West, Kelly M., 641-644
 West, Lester, *690
 Westbie, D.K., *448
 Westfall, Thomas C., *414, *1034
 Wheeler, Lawrence, 820-828
 White, Priscilla, 559-565, 672-679
 Whitehouse, F.W., *436
 Whitehouse, Iris J., *436
 Whitesell, Richard R., *448
 Wichser, J., *781
 Wicks, A.C.B., *694
 Widerlite, Laurence, *389
 Wieser, Paul B., *690
 Wilke, H., *389
 Wilkins, S., *408
 Willerson, James T., *694
 Williams, A.D., 1081-1085
 Williams, Gerald A., *58, *443, 922-925
 Williams, Gordon H., 190-193
 Williams, J.F., *386
 Williams, Paul R., *411, *604-605,
 *1036
 Williams, Robert H., 238-239
 Williams, T. Franklin, *431
 Wilmore, D.W., *694
 Wilmshurst, E.C., 672-679
 Wilson, L.M., *57

- Wilson, Walter R., *401
 Wingerd, John, 449-451
 Winegrad, Albert I., *1126
 Winkler, G., 988-996
 Wise, Jonathan, *1128
 Wongsurawat, N., *443
 Woodbury, C., *418
 Woodrow, J.C., 345-349
 Woods, Stephen C., *408, *414,
 905-909, 910-914
 Wright, Peter H., *409
 Wu, Ching-Hui, *694-695
 Wyse, Beatrice M., *448

Y

- Yamagata, Shoichi, 811-819, *1128
 Yamaoka, Y., *242-243, *309
 Yanbe, Akira, *1128
 Yasuda, Keigo, *1037, 1066-1071
 Yeast, J., *400
 Yeomans, Lynne, *56-57
 Yeh, Mary, 842-850
 Yip, C., *441
 Yodaiken, Ralph E., 286-290
 Yoo, Jinil, *695
 Yoshida, Kohjiro, 1-9
 Yoshida, Michio, 971-976
 Yoshinaga, Kaoru, *1037, 1066-1071
 Yoshitoshi, Yawara, *56
 Young, Eleanor A., *695
 Young, H.S., *407
 Yue, D.K., 625-632

Z


- Zatrici, A., *419
 Zawulich, W.S., *405
 Zelig, Harry, *241, *307
 Zermatten, Antoine, *413
 Ziegler, M.M., *418
 Zimmerman, C.E., *437
 Zingg, W., *404
 Zoneraich, Samuel, *242, *691
 Zernaviezky, J., *389
 Zucker, P., 194-200
 Zuhlke, H., *399

DIABETES: VOLUME 24 (1975) PAGE NUMBERS BY ISSUE

January, 1-64
 Supplement 1, 65-184
 February, 185-248
 March, 249-312
 April, 313-392

Supplement 2, 393-448
 May, 449-528
 June, 529-608
 July, 609-704

August, 705-784
 September, 785-864
 October, 865-960
 November, 961-1040
 December, 1041-1136



American Diabetes Association, Inc.
1 West 48th Street (600 Fifth Avenue)
New York, N.Y. 10020

